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Abstract.
A multilocus sequence typing (MLST) system for group B streptococcus (GBS)
has been developed and validated on a global collection of human GBS strains
isolated from carriage and invasive disease.
A carriage study was performed, over a 3-year period, to establish the
rate of carriage ofGBS in pregnant women in Oxford, UK. Invasive isolates
were collected, prospectively and retrospectively over a similar time period.
Twenty-one percent of women studied were asymptomatic carriers of
GBS. The incidence of invasive GBS was 0.9/1000 live births in neonates and
6.11100,000 population >60 years.
The population structure of GBS is best depicted. using MLST. as a
network of related clusters indicating the presence of recomb inationa Ievents
occurring in the population that interfere with a tree like branching structure of
the population.
A single hypervirulent clone ofGBS (ST-17 complex) is responsible for
an excess of neonatal disease in Oxford (odds ratio 3.4). The possibility that a
factor other than capsular type IIImay be responsible for virulence of this clonal
complex in neonates is raised. Intriguingly this clonal complex was unique
among human lineages in that it has emerged from bovine GBS. It was not
however associated with increased invasiveness amongst adult (> 60 years).
Further study ofthis hypervirulent clone of GBS is likely to contribute to
the understanding of the pathogenesis of neonatal GBS disease.
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Chapter 1: Introduction
1.1 GROUP B STREPTOCOCCUS:
1.1.i Historical perspective:
The first descriptions of human disease caused by Lancefield group B ~-
haemolytic streptococcus, Streptococcus agalactiae, were fatal cases of
puerperal sepsis in 19351• Occasional reports appeared in the literature over the
next few decades, but it was only in the 1970s, when a dramatic increase in cases
was reported, that group B streptococcus (GBS) was recognised as the leading
cause of human neonatal sepsis in geographically diverse regions'".
1.1.;; Microbiology:
Streptococcus agalactiae is the species designation of GBS. It is a facultative
anaerobe and a Gram-positive coccus occurring in pairs or short chains. Colonies
on agar supplemented with horse or sheep blood appear as mucoid, are coloured
grey, buff or white, are 3-4mm across and are surrounded by a thin rim of ~ -
haemolysis.
Definitive identification requires detection of the group B carbohydrate antigen
usually by serological methods, first described by Rebecca Lancefield 5.
Commercial kits based on latex agglutination are commonly used in clinical
microbiology laboratories.
Other biochemical tests have been employed for presumptive identification of
GBS including: resistance to bacitracin, hydrolysis of sodium hippurate broth.
failure of hydrolysis of bile-aesculin agar (BAA), pigment production on certain
media in anaerobic growth conditions" and production of CAMP factor 8.
l.Liii Typingmethods/or GBS:
There is a type-specific polysaccharide capsule on the GBS surface 9. Nine
capsular types have been characterised, lA, IB, II to VIII and have traditionally
been the method of distinguishing between strains.
Several molecular techniques including restriction digest pattern (RDP) typing!",
pulse field gel electrophoresis (PFGE)II and multilocus enzyme electrophoresis
(MLEE)12.l3 have been used on collections ofGBS, but there has been no
universally accepted typing method other than capsular serotyping.
l.l.iv Virulence o/GBS:
The role of type specific polysaccharides in virulence ofGBS has been evaluated
in murine!" and chick models 15,where the amount of capsule was found to
correlate with invasiveness. In addition, a capsule-free mutant strain ofGBS was
effectively cleared in a murine model !". The component monosaccharides of
the GBS capsule are repeating units of galactose, glucose, N-acetylglucosamine
and sialic acid 17-24.Sialic acid as a terminal side chain residue is a consistent
feature and in the cases of type lA, lB and III polysaccharides there is a high
degree of structural homology with two human serum glycoproteins, the M and
N blood group substances 25.The type III capsule is structurally homologous and
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immunochemically identical to the pneumococcal type 14 polysaccharide 26.
Molecular mimicry of host surface structures resulting in poor recognition and
opsonophagocytosis of the encapsulated bacteria is believed to account at least
in part, for the virulence ofGBS.
The haemolysins of GBS are an extracellular product of almost all strains and
are active against the erythrocytes of several mammalian species 27. Mutant GBS
lacking haemolysin, however, did not differ in virulence to wild type in a
neonatal rat model28. More recently, using a murine model, B-haemolysin
induced nitric oxide production and septic shock.
Most strains of GBS elaborate C5a peptidase, a serine protease that inactivates
the human complement component C5a 29. It is thought that C5a peptidase
contributes to virulence by preventing neutrophil accumulation at the site of
infection 30 and by promoting fibronectin binding. There is similarity between
GBS C5a peptidase and a similar molecule in group A streptococcus 31.
Neuraminidase, possibly a hyaluronate lyase, active against host sialic acid
substrates, may also be associated with virulence 13. GBS synthesise lipoteichoic
acid and other teichoic acids that facilitate attachment to human cells 32.
1.1.v Epidemiology of human GBS infections:
1.1.v.a Asymptomatic colonisation. The primary reservoir for GBS is
likely to be the lower gastrointestinal tract of men and women. Studies ofGBS
3
carriage are difficult to compare directly because of differences in methodology,
particularly the body sites sampled and the microbiological methods used. It is
estimated that up to 30% of healthy adults are carrying the organism33-38•
Efficiency of identification of female genital GBS carriage increases when
sampling is from the vulva or low vagina. Sampling of both lower genital and
rectal (vagino-rectal) areas identifies 10-15% more carriers than if a single site is
cultured 39-41. Isolation rates are significantly higher when broth rather than solid
agar is used. Selective media 42-44, containing antibiotics inhibitory to the normal
flora, typically gentamicin 4-8 mcg/ml and nalidixic acid 15 mcg/ml33also
increases the yield ofGBS in culture.
Cultures performed 1 to 5 weeks before delivery are accurate in predicting GBS
colonisation status at delivery in women at term. One study reported a positive
predictive value of87% and a negative predictive value of96% when cultures
were carried out in this time interval 45. Longitudinal studies of genital tract GBS
colonisation in pregnant women (n=382) showed that carriage was chronic in
36%, transient in 20%, intermittent in 15% and indeterminate in 29% 46.
Several factors have been associated with an increased risk ofGBS carriage in
studies of pregnant and non- pregnant women. These factors include, diabetes
mellitus", tampon use 48, age <20 years 49, Hispanic and African-American race
50 and intrauterine device use 51. Factors that do not seem to affect prevalence of
GBS carriage are use of oral contraceptives 40, marital status, sexually
transmitted infections and number of sexual partners 52.
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l.l.v.b Transmission to the neonate. Exposure of the neonate to
GBS in the maternal genital tract at delivery occurs by ascending infection
through ruptured membranes in utero, or by contamination during passage
through the birth canal. The mean rate of transmission ofGBS from a carrier
mother to her neonate is 50%, whereas only about 5% of neonates of culture-
negative mothers become GBS colonised within 48 hours of life 53.54.Vertical
transmission appears to be more likely where there is heavy colonisation of the
mother 55.The neonatal colonisation tends to be of surface and mucous
membrane sites and can persist for weeks 39.Horizontal transmission ofGBS to
the neonate from hospital or community sources also occurs 56.
Infants asymptomatically colonised from a maternal source in the peripartum
period have persistent carriage ofGBS for weeks57.58. Although horizontal
transmission ofGBS to the neonate can occur in maternity units or in the
community it appears to be unusual. In a study of 46 neonates GBS culture-
negative on discharge from hospital, only 2 had mucous membrane carriage at 2
months of age57-59.
l.l.v.c Neonatal Invasive disease. There are two distinct
syndromes of neonatal GBS infection, termed early-onset «7days of age) and
late-onset (7-90 days of age) sepsis. Prevalence ofGBS bacteraemia is 0.560 to
3.761 /1000 live births for early- onset and 0.3 60to 1.811000 41live births for late-
onset sepsis. In the USA, the incidence of early-onset disease has decreased by
65% from 1993 to 1998 from 1.7 to 0.6/1000 live births as a result of the use of
5
intrapartum antibiotic prophylaxis (lAP) 62. Stratification of attack rates of early-
onset GBS infection by birth weight shows that lower birth weight categories
have higher rates of infection 63.
When probable, as well as definite neonatal infection (Table 2.5) is studied, the
incidence rates of neonatal GBS infection are higher64.65• Higher rates of early
onset neonatal GBS disease, 1.5/100066, were described in the USA prior to the
introduction of preventative strategies in 1994. This has now dropped to
0.5/100067 since those strategies have been introduced.
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Table 1.1: Studies estimating early and late onset neonatal sepsis from 1990 to
2003.
Study Year Early-onset Late-onset Overall Ref
neonatal neonatal
infection infection
Bedfordshire, 2000 1.15 ND NO 68
UK (0.6- 1.7)
London, UK 2003 3.6* NO NO 65
(1.9- 5.3)
Oxford, UK 1998 0.9* NO NO 69
(0.7- 1.3)
London, UK 2001 2.6* ND NO 64
National, UK 2001 0.5 0.3 0.8 60
(0.5- 0.6) (0.7-0.9)
Sunderland, UK 1999 0.95 0.47 1.42 70
(0.8-2.0)
Finland 2003 0.65 ND ND 71
(0.6- 0.7)
USA 1990 1.5 0.3 1.8 72
USA 2000 0.5 ND ND 67
(0.4-0.6)
Footnote to Table 1.1: Figures are expressed as number of cases/l 000 live births
of invasive neonatal GBS infection. Ninety-five percent confidence intervals are
indicated in parentheses, where available. Infection was diagnosed by culture of
GBS from a normally sterile site (definite infection).
*definite and probable GBS infection included in estimate of incidence.
Abbreviations: NO, not done.
Early onset GBS infection commonly presents as bacteraemia without a focus
(25 to 40%), pneumonia (35 to 55%) and meningitis (5 to 10%). Hypotension
and respiratory abnormalities are early signs. Other signs are lethargy, poor
feeding, hypothermia, fever, abdominal distension, tachycardia and jaundice
73 74 I c. ti " be associ d . h f I h .. . nrec Ion occurrmg In utero may e ass ciate WIt oeta asp yxia,
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Meningitis can present in the same way as bacteraemia 75, thus cerebrospinal
fluid (CSF) examination is the only reliable means to exclude the diagnosis,
Seizures may complicate meningitis, Radiological findings of pneumonia are
indistinguishable from hyaline membrane disease 76, Mortality rates are between
5-10% 73,74, Features associated with a poor outcome are low APGAR score at
birth, shock, coma, neutropaenia, pleural effusions, apnoea, delayed diagnosis
and prematurity 77.78,
Late onset GBS infection occurs in infants who typically have an unremarkable
early neonatal history, Meningitis is the presentation of 35-40% of cases, with
bacteraemia with no focus occurring with similar or higher frequency 41, Other,
less common, manifestations of late onset infection are osteomyelitis, septic
arthritis, cellulitis and adenitis 79-81. Meningitis typically presents with fever,
irritability, lethargy, poor feeding and tachypnoea, Complications include,
seizures, status epilepticus and coma, and are markers of a poor outcome, with
approximately 26% of cases being fatal 54,77, Subdural empyema and
hydrocephalus requiring shunting can also occur 82, Permanent moderate or
severe neurological sequelae are present in about 21% of cases 83,
Approximately 0.5 to 3% of neonatal patients have relapsed or recurrent GBS
infection, occurring up to 4 months after treatment 84-86, Persistence of the
organism on mucous membranes 87 or in a deep site 88.89, inadequate therapy and
tolerance ofGBS to penicillin 90 are factors implicated in recurrence,
8
1.1.v.d GBS infection acquired during adulthood. More than
two-thirds of OBS disease in the USA occurs in adults". OBS infections
commonly affect those with underlying medical conditions, especially diabetes
mellitus. Other medical conditions, which predispose to OBS invasive infection
are liver cirrhosis, malignancy, vascular disease and decubitus ulcers'" . In
studies, 70-93% of adult patients with OBS infection had one or more
underlying medical illness62.93,94.
The mean age of non-pregnant adults with invasive OBS disease is 60 years and
elderly adults in nursing home accommodation appear to be at particular risk 95.
Annual incidence rates of OBS disease in adults have been estimated in the USA
as 4.1 to 7.2/100,000 population 95.
GBS is a common maternal pathogen in the perinatal period. It is responsible for
chorioamnionitis, urinary tract infection, postpartum endometritis and wound
infection after caesarean section (CS). It has been estimated that the attack rate
for maternal OBS puerperal sepsis is 211000 96. Pregnant women account for 10-
15% of cases of adult OBS bacteraemia 72.
1.1.vi BovinegroupB streptococcalinfections:
GBS is a highly contagious pathogen of the bovine mammary gland. The
organism can persist for many months in an individual and can spread to infect
herds of dairy animals. It is unclear whether host-specific ecovars exist in cattle
and humans. Contradictory reports indicate the absence or presence of a
relationship between human and bovine OBS isolates.
9
Bovine mastitis has been induced artificially using both human and bovine-
derived GBS strains". A study of Slovenian dairy farms, suggested that farm
workers were carrying the same capsular serotypes ofGBS as their cattle".
Using MLEE, Musser and colleagues demonstrated that human and bovine GBS
strains fell into the same lineages, although the numbers studied were small':'. In
contrast, RAPD (random amplified polymorphic DNA) typing of GBS revealed
that there was little overlap between human carried and bovine mastitis causing
GBS strains isolated in Canada'", The exact relationship between human and
bovine derived GBS is yet to be determined.
l.l.vii Treatment of human GBS disease:
GBS remains susceptible to penicillin and resistance has not been reported 100
Penicillin G is the drug of choice for the treatment of invasive infections. Other
p- lactam antibiotics, including the carbapenems and many of the cephalosporins
are active against GBS. Duration of therapy has not been extensively studied, but
the traditional course of penicillin for neonatal bacteraemia is 10 days and longer
courses (2-6 weeks) have been suggested where there is endocarditis, meningitis
or osteoarticular disease. Initial therapy including synergistic aminoglycosides
may be superior to p-Iactams alone 101. Interestingly, in vitro studies have
suggested that chloramphenicol and rifampicin may antagonise the effect of p-
lactam agents on GBS and are generally not recommended 102,103.
Increasing resistance to certain groups of antibiotics has occurred in GBS. In
particular rates of tetracycline resistance have increased from 30% in 1950 to
10
90% in current times. Resistance to erythromycin and clindamycin have also
increased and exceed 40% in Taiwanl04. A recent estimate of the prevalence of
erythromycin resistance in UK GBS isolates is 10%.
I.l.viii Prevention of neonatal GBS disease:
The basic strategies in the prevention of neonatal GBS are directed either at
eliminating exposure (chemoprophylaxis) or enhancing immunity
(immunoprophylaxis ).
1.1.viii. a Chemoprophylaxis. Early studies in the 1970s of
administration of oral penicillin to GBS colonised women late in pregnancy
proved to be ineffective in the prevention of invasive neonatal infection 105. The
inherent difficulty of eradicating an organism with a reservoir in bowel flora is a
likely explanation for this finding. Intravenous antibiotics administered during
labour were investigated in 1979 and the interruption of transmission of GBS to
the neonate was impressive 106. Further studies confirmed the findings and
extended the beneficial effect of the intravenous antibiotics to the treated
mothers 55.107, who suffered less GBS related infectious morbidity 55.
It is generally accepted that lAP with intravenous penicillin is the most effective
method, in the current setting, of preventing neonatal early-onset GBS infection.
The incidence of late-onset neonatal infection has not however been affected by
this strategy. Over the past two decades. debate has continued as to which
groups of women should be offered lAP. The two main strategies proposed in
the CDC (Centres for Disease Control and Prevention, Atlanta, USA) consensus
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guidelines 33 were based upon the results of vagino-rectal culture or assessment
of risk-factors in the pregnant woman.
The culture-based approach identifies women for lAP following identification of
GBS in vagino-rectal swabs cultured in selective broth taken at 35-37 weeks of
pregnancy. The risk-factor approach identifies women to be offered lAP
according to the presence of factors, which are known to increase the likelihood
of neonatal GBS disease. The factors include onset of labour prior to 37 weeks
of pregnancy, intrapartum fever and rupture of membranes more than] 8 hours
before delivery 108. In either strategy, a previous infected neonate and the finding
ofGBS bacteriuria are further factors identifying women for lAP. Following
either strategy, approximately 25% of pregnant women are given lAP. The
proportion of disease theoretically prevented by the culture-based approach is
higher (85-90%) than that prevented by the risk factor approach (50-65%).
Following implementation of these guidelines in the USA neonatal early onset
GBS infection was reduced by 65% to 0.6/1000 62.
1. 1. viii.b Immunoprophyiaxis. Vaccination of all women of
child-bearing age either before or during pregnancy is the most promising
strategy for the prevention of neonatal GBS infection 109,110. Human sera
containing type III specific capsular antibody is protective against lethal
challenge in animal models II Ll12. Type-specific antibody is thought to be
protective in human disease 113.114. Protection of the newborn could theoretically
be achieved through immunisation of the mother. Purified capsular
polysaccharides (lA, II, III, V) have been utilised in clinical trials in adults and
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have been associated with an immune response 115.116. Protein conjugate capsular
polysaccharide vaccines may have increased immunogenicity. Initial results of
conjugate tetanus- toxoid polysaccharide vaccines have revealed them to be safe
d i .. dl 1171180th .. 1 ·1 ·1· biouian immunogenic In a u ts '. er vaccmes In ear y tria s uti rse u iquitous
OBS surface proteins, such as C5a peptidase 119and Sip protein 120.
1.2 POPULATION BIOLOGY OF PATHOGENIC BACTERIA:
1.2.i The clonal model of population structure of bacteria:
Pathogenic bacteria exist as populations, the members of which exhibit varying
degrees of virulence. The study of evolution, epidemiology and population
genetics can provide important insights into the origins and spread of pathogenic
bacteria and is helpful in the design of effective public health interventions. In
recent times, with the advent of automated high-throughput DNA
(Deoxyribosenucleic acid) sequencing, closer study of the complexities of the
evolution of bacterial populations is now possible!".
The clonal population structure is a popular paradigm for the exploration of
bacterial population diversity. The basis of the model is that haploid bacteria
reproduce asexually by binary fission and chromosomal variations occur by de
novo mutations, leading to linkage disequilibrium between alleles at different
loci. This contrasts with populations of sexual organisms where mutations are
constantly re-assorted, resulting in linkage equilibrium, meaning that mutations
at different sites occur in random combinations. Diversity can arise in asexual
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populations by other mechanisms, such as the gain and loss of plasmids or the
movement of insertion sequences. Differences in the frequencies of particular
lineages in the population will occur over time as a result of stochastic events
and selection. Bacterial populations are also subject to rapid expansions and
bottlenecks, which can also reduce the diversity of clonal populations. While
limited diversity is predicted under the clonal model, it is not the only reason
why a bacterial population may be uniform and lack of diversity alone should
not be used as proof of clonality",
In reality, bacteria rarely conform entirely to the idealised clonal model123.The
complications of bacterial population biology arise from the fact that while
bacteria are largely asexual, they possess a number of mechanisms for the
horizontal transmission of genetic material and recombination, including
plasm ids, prophages, transposons and insertion sequences. The bacterial
genomes therefore become pocked by small chromosomal replacements from
other lineages. The frequency of such recombinational replacements in bacterial
species may vary from very low to very high relative to mutational rates.
Horizontal genetic exchange can account for increased diversity in bacterial
populations, but may also allow a successful allele to spread horizontally in a
population replacing other variants and thereby reduce diversity at a locus.
Differences in the ratio of genetic change caused by recombination relative to de
novo mutations leads to a spectrum of population structures from the extremes of
clonal, with no recombination to non-clonal or panmictic where recombinational
exchanges are sufficiently frequent to randomise the alleles in the population.
Most bacterial species probably occupy the middle ground.
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In the study of the population biology of bacteria, important considerations are
the assembly of representative collections of the organisms and accurate and
appropriate characterisation. Unfortunately most existing culture collections are
rarely representative of biological or natural populations as they frequently
concentrate only on the most virulent, medically important isolates. As many
bacterial pathogens do not rely on the generation of a pathological condition for
transmission or their long-term survival, but cause disease accidentally or
opportunistically, bias is introduced into the collections. These problems can be
addressed by sampling strategies that take into account the biology of the
particular pathogen, usually necessitating the establishment of structured
sampling programmes'<. The strategy for obtaining an appropriate sample of the
bacterial population is also species specific, for an obligate human pathogen, a
collection of disease causing isolates from global sources is likely to sample
more of the natural population of that organism when compared to a pathogen
that is normally a commensal, such as OBS. In the latter case, a representative
sample of the entire population must mainly comprise isolates from healthy
carriers. Itmay also need to take into account other sources of that organism,
such as other non-human species or the environment.
Serological typing has been a popular method of characterising bacterial
pathogens, including OBS for many years. However, as the entities detected by
serological tests are usually located on the surface of the cell, the corresponding
genes are likely to be under strong diversifying selective pressure by the host
immune system and evolve rapidly. Only rarely will such markers provide
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reliable information on the phylogenetic history of a species and may give highly
misleading information about mutational rates and recombination. In the study
of bacterial population structure, it is therefore preferable to utilise genetic
variation that is neutral. Housekeeping genes, such as those involved in central
metabolism, are suitable in this respect as they are responsible for essential
biochemical processes, where functional constraint is likely to be highl24•
Prior to the introduction of automated DNA sequence determination, MLEE was
the method of choice for analysis of bacterial population structure. This is an
indirect method in which electrophoretic mobility of enzymes infers genetic
variation in housekeeping genes. The disadvantages of MLEE compared with
sequence based methods, other than technical difficulty, are that the only genetic
changes that are detected are those which alter electrophoretic mobility and that
enzymes with the same electrophoretic pattern could have different sequences'j".
1.2.ii Multilocus Sequence Typing:
Multilocus sequence typing (MLST) was proposed in 1998 as an approach,
which could provide accurate data, appropriate for the epidemiological
investigation of bacterial pathogens and which could reflect evolutionary
biology'<', MLST is a sequence based typing method, which was developed
using the principles of MLEE. Genetic variation in housekeeping genes
continues to be the focus of study, but nucleotide sequence determination rather
than electrophoretic mobility, identifies this variation. The advantages of
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nucleotide sequencing include generic methodology and ease of comparison
electronically. Automation is a realistic possibilityl21.124.
The design of an effective multi locus sequence typing system is dependant on
several factors. The assembly of a collection of isolates is critical and at least for
the initial evaluation should be from diverse sources representing the ecology of
the organism (as described above). Other factors include, the choice of genetic
loci to be characterised, the design of primers for gene amplification and
nucleotide sequence determination and optimisation of amplification
reactions 125.
MLST can be used to provide access to data using the internet through the
creation oflarge databases!" which can be accessed at http://www.mlst.net.
These databases, in addition to being virtual isolate collections, contain
epidemiological and clinical information and other typing results, such as
serotype.
1.2.ii.a Analysis of MLST data. The clonal complex, utilised
in the analysis of MLST data comprises genetically related but not identical,
bacteria". Many datasets will contain large numbers of allelic profiles or
sequence types (STs), but analysis reveals that some are numerically more
significant than others. Using techniques such as BURST (START version 1.05,
http://www.mlst.net) or split decornposition'r", it can be seen that these
prevalent allelic profiles are frequently centrally located and have numerous
relatives derived from them by a limited number of genetic events. These central
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genotypes form the basis of the naming system of the clonal complexes, e.g. ST-
23 complex of GBS has ST-23 as its central genotype. Organisation of data into
clonal complexes allows easier epidemiological analyses'P,
Nucleotide sequence data from multiple housekeeping genes in an appropriately
sampled population can be used in a variety of analyses. The simplest is to
establish the alleles present at each locus and to use a clustering algorithm to
determine the relationships between strains from the matrix of pairwise
differences between their allelic profiles. While this is effective in establishing
that isolates are identical or closely related, the approach will not provide much
information about the relationships between more distantly related isolates,
unless the population structure is strictly clonal.
Additional phylogenetic information can be recovered if the nucleotide
sequences themselves are analysed. Measures of genetic change, which take into
account the actual number of base changes between sequences rather than just
whether the sequences are the same or different are more informative. One of the
most common of these measures is the nucleotide diversity (or 1t) that represents
the average number of nucleotide differences per site between two sequences.
The number of variable nucleotide sites in a sample of sequences is denoted as S
(or segregating sites). In order to be comparable across datasets, SIL, where L is
the sequence length is a better measure of genetic diversity. Another indication
of molecular genetic variation in populations is the average number of pairwise
differences between sequences (IT).
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Traditionally, phylogenetic data are depicted as a tree like structure. A tree is a
mathematical structure, which is used to model the actual evolutionary history of
a group of sequences. A phylogenetic tree is composed of branches and nodes.
Branches connect nodes and a node is the point at which 2 or more branches
diverge. Nodes can be internal, corresponding to the hypothetical last ancestor
and external (terminal), which correspond to the sequences from which the tree
is constructed 128.
Molecular phylogenetic trees are usually drawn with proportional branch
lengths; that is the lengths of the branches correspond to the amount of evolution
between the two nodes they connect. The longer the branch, the more divergent
are the sequences attached to them.
Molecular trees are based on multiple sequence alignments and are commonly
constructed by the method known as "progressive sequence alignment". This
method builds up alignment in stepwise fashion, starting with the most similar
sequences and progressively adding the more dissimilar ones. A crude guide tree
is formed which is then built upon 128.
The methods for calculating trees fall into 2 general categories. Distance-based
matrix methods, also known as clustering or algorithmic methods (e.g.
Unweighted pair group method with arithmetic means (UPGMA), neighbour-
joining) and discrete data methods, known as tree-searching methods
(maximum-likelihood, parsimony). Distance methods are simple and are rapidly
calculated. The "distance", the percentage sequence difference, is calculated for
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all pairwise combinations of sequences and the distances are assembled into a
tree. Discrete data methods examine each column of the alignment separately
and look for the tree that best accommodates all of this data. For these reasons,
the discrete data analyses contain more information 128.129.
Once the tree has been generated, its accuracy can be tested. The simplest test of
phylogenetic accuracy is the bootstrap. Bootstrapping essentially tests whether
the dataset is supporting the generated tree. Random sub-samples of the dataset
are taken, trees are built from these and the frequency with which the various
parts of the tree are reproduced in each of the sub-samples is calculated. The
bootstrap value given to a group is the percentage of occasions where that group
is found in sub-sample trees. Bootstrap values of 70% or higher are thought to
. di I' bl . 128m icate re la e groupmgs .
There are well-described pitfalls identified in phylogenetic tree construction.
One of these is a phenomenon described as "long branch attraction" 128. This is
the tendency of highly divergent sequences to group together in a tree regardless
of their true relationships. One effect of this is that bootstrap values all over the
tree disintegrate. Removal of divergent sequences may reveal more accurately
the relationships of the remaining strains in the collection.
Displaying evolutionary relationships as phylogenetic trees implies that
evolution is a branching or tree-like process. However, a set of data often
contains a number of different or conflicting signals, which may not support a
tree structure. To address this problem the method of split decomposition was
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developed 127. In contrast to methods like maximum parsimony, that reconstructs
trees by optimising certain parameters, split decomposition is a transformation-
based approach. The evolutionary data are transformed or more precisely
canonically decomposed into a sum of weakly compatible splits and then
represented by a splits graph. For some data this is a tree, whereas other data will
give rise to a tree-like network that can be interpreted as possible evidence for
different and conflicting phylogenies. Furthermore, as split decomposition does
not attempt to force data onto a tree it can provide a good indication of how tree
like given data are. This is depicted graphically in Figures 1.1 and 1.2 where the
tree like structure imposed on the data by the algorithms ofUPGMA is then
depicted as a network relationship ofSTs when analysed using split
decomposition.
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Figure 1.1: UPGMA tree (with bootstrap values) generated using concatenated
sequence data for 5 STs ofGBS.
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Figure 1.2: Tree generated using concatenated sequence data by split
decomposition of 5 STs of GBS showing a network relationship of strains.
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1.2.;;; The evaluation of a typing system.
The discrimination of bacterial pathogens on the basis of genetic or phenotypic
markers is imperative in descriptive epidemiology. To be able to investigate the
diversity of organisms in defined environments and to describe the spread of
particular strains of pathogen between hosts, it is essential to deploy a typing
technique, which has the ability to distinguish between diverse strains of that
organism.
Capsular serotyping is the technique that has been most commonly utilised and
is the gold standard method for sub-typing of GBS. There is no standardised
method for capsular serotyping therefore methodology varies between
laboratories. The commonly used techniques rely upon the development of
monoclonal antibodies against the 9 GBS capsular types and detection of
agglutination using latex, capillary diffusion or other methods. Capsular
serotyping has been popular because it is reasonably inexpensive and technically
not demanding. Non-typable isolates, however, are fairly common in humans
and much more common in bovine GBS. In addition, discrimination is thought
to be less when compared with MLEE, RDP typing and PFGE, where isolates
with the same capsule can be genotypically distinct.
In the evaluation of the efficiency a new typing system, typability,
reproducibility and discrimination 130 are assessed. The typability of a method is
the percentage of distinct bacterial strains, which can be assigned a positive
typing marker. Reproducibility is the percentage of strains that give the same
result on repeated testing. The discriminatory power is the ability of the method
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to distinguish between unrelated strains. It is determined by the number of types
defined by the test method and the relative frequencies of these types. It has been
difficult to define discrimination using a single comparative statistic. Hunter et
all3l have suggested the use of the Simpson's Index of Discrimination (D) as a
single numerical index of discrimination, based upon Simpson's index of
population diversity'F, The index calculates the probability that two unrelated
strains sampled from the same population will be placed in different typing
groups.
1.3 AIMS OF THIS PROJECT:
The aims of this study are to investigate the population biology of an important
human pathogen, GBS, and to determine whether hypervirulent clones of GBS
(that is clones of GBS which are over represented in invasive disease rather than
carriage and are therefore likely to be associated with virulence determinants)
can be identified and correlated with disease in humans.
I. To develop a multilocus sequence typing system for GBS which could
then be used to examine the population biology ofGBS.
2. To validate the GBS MLST system on a global collection of human
isolates isolated from carriage and invasive disease.
3. To investigate the population biology of GBS on assembled collections
of GBS representing human carriage and disease in neonatal and adult
groups from a single geographical area (UK).
4. A further aim was to examine bovine GBS and its relationship with
human GBS.
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Chapter 2: Materials and Methods:
Generic methods are described below. Additional methods specific to a
particular study are included in the chapter describing that study.
2.1 MICROBIOLOGY METHODS:
2.1.i Identification ofGBS:
Group B streptococci were cultured in the laboratory on Colombia agar plates
containing 5% horse blood and identity confirmed as GBS according to standard
methods. Incubation of plates was carried out overnight in a humidified
atmosphere enriched with carbon-dioxide (5%). White or buff coloured
glistening, mucoid colonies approximately 1-3 mm in diameter surrounded by a
small zone of ~-haemolysis were further identified. Catalase-negative, Gram-
positive cocci in pairs or short chains were confirmed as GBS using the rapid
latex agglutination test (Oxoid, Basingstoke, UK), which detects the Lancefield
group B antigen.
2.1.ii Lancefield group B antigen detection by latex agglutination:
All reagents, antisera and controls were provided by Oxoid, Basingstoke, UK. A
small glass test-tube was labelled for each organism to be tested and for a
positive control. One hundred and fifty microlitres of extraction enzyme was
added to each tube. Approximately five colonies were picked off and emulsified
into the extraction enzyme with a flamed platinum loop. The tubes were
incubated in a water bath at 3TC for 10- 15mins. Antisera for Lancefield
antigen H, D, and F were tested against each isolate. Agglutination confirmed
the presence of the Lancefield B antigen.
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2.1.;;; Assembly of freezer files ofGBS isolates:
Isolates of GBS for study were kept frozen at -80°C in Tryptone-soy broth with
glycerol (10%).
2.1.iv Capsular serotyping methods:
The capsular serotypes of the GBS isolates were determined using latex
agglutination. The methods followed were based upon those ofSlotved et all33•
Antisera to the nine GBS serotypes (lA, IB to VIII) were supplied by State
Serum Institute, Denmark. Strains were cultured overnight on blood agar plates
then inoculated into Todd-Hewitt broths (lml) in sterile capped tubes. Tubes
were incubated overnight at 3TC. On a glass slide IIIIof antisera was mixed
with 5111of broth suspension of organism. The slide was rocked for a maximum
of 30 seconds. Agglutination indicated a positive reaction.
2.2 MULTILOCUS SEQUENCE TYPING METHODS:
2.2.; Extraction of DNA from isolates:
A kit method (Qiagen DNeasy kit) was followed. All reagents were supplied by
Qiagen, Germany, other than those for enzymatic lysis buffer, which were
supplied by Sigma, USA. Isolates were sub cultured from -80°C freezer vials to
5% horse blood agar plates and incubated overnight as described. Using a sterile
loop, a single colony from the blood agar plates was streaked out onto a second
blood agar plate and overnight incubation repeated.
Following incubation, approximately 5 colonies from the blood agar plate were
used to inoculate 200lli Phosphate Buffered Solution in a sterile tube. Tubes
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were centrifuged at 5,500 x g for 10 min. The supernatant was poured off, being
careful not to disturb the pellet.
The bacterial pellet was resuspended in 180 III enzymatic lysis buffer, containing
20 mM Tris-CI (pH 8.0), 2mM Ethylenediaminetetraacetic acid (EDTA), 1.2%
Triton® X-lOO and 20 mg/mllysozyme. The tubes were incubated in a water
bath at 37°C for 30 minutes. Then 25 III Proteinase K and 200 JlI Buffer AL were
added and incubation continued at 70°C in a water bath for 30 minutes. Ethanol
96% (vol.lvol.) 200lli to precipitate the DNA was added to the sample and
mixed by vortexing. This mixture was pipetted into the DNeasy mini columns
(Qiagen) and centrifuged at 5,500 x g for 1 minute. The flow through and
collection tube were discarded and the column placed into a fresh collection
tube. The column was then washed using ethanol-based buffers (AWl and AW2,
Qiagen). The DNA was eluted in sterile water and then stored frozen at -20°C.
2.2.i; Polymerasechain reaction (peR) methods:
The methods utilised for PCR, DNA precipitation and sequencing were based
upon those in use in the host laboratory and have been published previouslyv".
Fifty microlitre PCR reactions were set up in 96 well plates. Each well contained
the following reagents:- Forward and reverse primers IIII each (Table 5.1, 100
pmol/ul, supplied by MWG-biotech, Germany), buffer 5111(MgCb 15mM, pH
8.7, lOx concentrated, Qiagen, Germany), dNTPs IIII (Deoxyribose nucleotide
triphosphate, 10 mM, supplied by ABgene, UK), Taq polymerase 0.51l1 (5
units/ill Qiagen, Germany), sterile water 39.51l1 and DNA template 2Jll. The
PCR cycle consisted of 30 cycles with denaturation at 94°C, annealing at 55°C
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and extension at 72°C. During development of the MLST system, the annealing
temperature was varied between 45 and 65°C in certain experiments.
2.2.;;i Demonstration of peR products on agarose gel:
Agarose gels were used for confirmation of the presence ofPCR amplicons.
Gels of 1% agarose (Helena Biosciences) were made using a base oftris-borate
EDTA buffer (TBE, 1x, Sigma, USA). Microwave heating dissolved the
agarose. Ethidium bromide (10mg/ml Sigma, USA) was added to the molten gel
to label DNA, with 1ul of ethidium bromide solution added to 50mls agarose.
Combs were placed in the liquid gel to generate wells of 10~1. The gels were
allowed to set at room temperature. Five microlitres of template, consisting of
2~1 PCR product and 3~1dye-loading buffer (Sigma, USA), were added to each
well. The Ikb DNA ladder (Promega) was used as a size marker (5~1per well)
for PCR amplicons of 500-700 base-pairs. Gels were placed in an
electrophoresis tank filled with TBE buffer (1 x) and electrophoresis proceeded
at 50-100 mV for 15-45 minutes. Gels were visualised using a UV camera and
the Molecular Analyst programme (version 2.1.2, BioRad Laboratories,UK).
2.2.iv Precipitation of peR amplicons:
All reagents were provided by Sigma, USA. Sixty microliters of20%
polyethylene glycol (PEG-8000) with 2.5M Sodium Chloride (NaCI) was added
to each peR reaction. Plates were then placed at room temperature for 30
minutes incubation. Centrifugation was then carried out for 60 minutes at 2,465
x g. The supernatant was then removed by spinning the plates upside down at 50
x g on paper towels. Two ethanol washes were then carried out with 150~1
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ethanol 70% (vol.lvol.) per well and centrifugation (2,465 x g) for 20 minutes.
The precipitated DNA was then dried by removal of supernatant (50 x g) and
incubation at 37°C for 15 minutes. DNA was eluted by the addition of lOul
sterile water per well.
2.2.v DNA nucleotide sequence determination:
Nucleotide sequences were determined at least once on each DNA strand using
internal nested primers (Table 5.1, concentration 1 picomols per Ill, MWG,
Germany) and ABI PRISM® BigDye™ Terminators v 3.0 Reaction Mix
(Applied Biosystems, Foster City, USA) in accordance with the manufacturer's
instructions. Sequencing reactions were carried out in 96-well plates, the forward
reactions were carried out in the left hand 48-wells of the plate and the
corresponding reverse reactions were carried out in the right hand 48 wells of the
plate. The sequencing reactions were carried out on the DNA engine using a
programme with 30 cycles of denaturation at 96°C, annealing at 50°C and
extension at 60°C. Unincorporated dye terminators were removed by
precipitation ofthe termination products with Sodium acetate (3M, pH 5.2) and
ethanol 96% (vol./vol.), and the reaction products were separated and detected
with an ABI PRISM® 3700 DNA Analyser (Applied Biosystems, Foster City,
USA). Sequences were assembled from the resultant chromatograms with the
STADEN suite of computer programs and edited to resolve any ambigutties".
The STARS software (available on www.mlst.net'r'") was used to reverse
compliment and align sequence pairs.
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2.2.vi Adaptations of methodfor tube reactions:
PCR and sequencing reactions were carried out in 200111PCR tubes, during
development and when small numbers of reactions were carried out. The
reactions were set up in the same way as those described above for the wells of a
96-well plate. Centrifugation was carried out at 15,700 x g for similar time span
as that described above for the plate centrifuge. Supernatant was removed by
pipette.
2.2.vii Allele and Sequence Type (ST) assignment:
For each locus, every different sequence was assigned a distinct allele number in
order of identification; these are internal fragments of the gene, which contain an
exact number of codons. Any change in the nucleotide sequence, whether or not
the amino-acid sequence is altered, was defined as a new allele. Each isolate was
therefore designated a seven-integer number, constituting its allelic profile.
Isolates with the same allelic profile were assigned to the same ST, which are
numbered in the order of their identification (ST-l, ST-2 etc). The data were
been deposited in a database accessible on the Internet at
hupi//sagalactiae.mlst.net'j".
2.3 COMPUTA TIONAL ANALYSES:
2.3.; Analyses based upon allelicprofile:
The START series of programmes were used to group STs into lineages or
clonal complexes using BURST (START version 1.05, http.z/www.mlst.net l'").
The members ofa BURST lineage were defined as groups of two or more
independent isolates where each isolate shared identical alleles at six or more
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loci with at least one other member of the group. UPGMA trees could also be
drawn from allelic profiles using the START software.
2.3.i; Analyses based upon nucleotidesequences:
Nucleotide sequence data were used to analyse the population structure of
collections of strains. Each strain was represented by a concatenated sequence.
That is, the sequences of the seven housekeeping genes were run together, so
that the unit of study was one long length of 3456 base-pairs, rather than seven
separate sequences of approximately 500 base-pairs.
Several software programmes were used to analyse nucleotide data from
concatenated sequences. Measures of genetic diversity and neutrality of
mutations were studied using DnaSP (DNA sequence polymorphism, version
3.99, www.ub.es/dnaspY). Phylogenetic trees were draw using the algorithms of
UPGMA, neighbour-joining and maximum-parsimony in the programmes
contained in MEGA (Molecular Evolutionary Genetic Analysis, version 2.1,
www.megasoftware.ner"). The split decomposition method was utilised and
resultant trees drawn by the SplitsTree programme (version 3.2,
http://bibiserv.techfak.uni-bielefeld.de/splitsI27). The significance of the tree
structures was calculated and Bootstrap values allocated to the branches using
either MEGA or SplitsTree.
A clonal complex was defined as closely related STs, which are grouped
together on a phylogenetic treel25.The clonal complex was named after the ST
identified by BURST as the central sequence e.g. ST-19 complex, or if BURST
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was not able to define the ancestor, then the most numerous ST became the
name of the complex e.g. ST-6 complex.
Diversity within and between clonal complexes was examined using
concatenated sequences. The analyses (carried out using MEGA) included the
number of segregating sites (S), the average number of pairwise nucleotide
differences (TI) and nucleotide diversity as measured by 1t. The number of
pairwise differences (TI) was estimated from the equation:
Figure 2.1 : Calculation of average number of pairwise differences.
1
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Where n is the number of sequences and n(n-l )/2 is the number of pairwise
comparisons and TIij is the difference between the ith and jth sequences. TI can
then be divided by L (the length of sequences, 3456 bp), where TIlL gives the
The Simpson's index of diversity (D) was used to assess diversity between
carried and invasive populations of GBS as it also takes into account the
frequency of allelic profiles represented in a collection. The index was calculated
according to the equation:
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Figure 2.2: Simpson's index of diversity.
D = 1 -
1 s
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Where N is the total number of strains in the sample population, s is the total
number of strains described and nj is the number of strains belonging to the jth
type.
The 95% confidence intervals (Cl) were calculated using the variance, ci, given
by the equation:
Figure 2.3: Calculation of variance of a population.
where Ttj is the frequency nj / n, TV is the number of strains belonging to the j th
type, and n is the total number of strains in the sample population. An
approximation ofthe 95% Cl is then given by the equation:
Figure 2.4: Calculation of Cl around the index.
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2.4 EPIDEMIOLOGICAL ANALYSES:
Epi Info 2002 software from the Centers for Disease Control and Prevention
(CDC, www.cdc.gov) was used to calculate odds ratios, 95% Cl and levels of
significance.
An empirical odds ratio (OR) was calculated to compare the probability of
invasive disease due to individual STs, clonal complexes or serotypes. The OR
was calculated by reference to all other serotypes or clones using published
methods 139 as follows: OR = ad/be, where a is the number of invasive A STs or
serotypes, b is the number of carried A STs or serotypes, e is the number of
invasive non- A STs or serotypes and d is the number of carried non-A STs or
serotypes.
Yates corrected test of significance was used to calculate p-values, except where
the value of a cell was less than 5, in which case the Fisher exact test was used.
2.5 ASSESSMENT OF DISCRIMINATION OF GBS MLST:
Quality control of MLST was achieved in several ways. Laboratory methods
were fastidious. A negative control (well containing sterile water in place of
DNA) and a positive control (strain with a known allelic profile) were included
on each 96- well plate. A random selection of PCR and sequencing reactions
were repeated to confirm allelic identity.
34
Simpson's Index of Diversity (D) (Figure 2.2) was used to determine the
discrimination of the MLST system and the capsular serotyping method for
OBS. The index calculates the probability that two unrelated strains sampled
from the same population will be placed in different typing groups. Ninety-five
percent Cl were calculated from the equations in Figures 2.3, 2.4.
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Chapter 3: Invasive GBS disease in Oxford, UK.
3.1 AIMS:
1. Development of a collection of invasive neonatal and adult isolates of
OBS for further study.
2. Assessment of the incidence of invasive OBS disease in population age-
groups in Oxfordshire.
3.2 INTRODUCTION:
The incidence of invasive GBS infection has been studied in some detail in
North America, and less so in the UK. A recent national surveillance project
took place in the UK and found that 0.8/1000 of neonates in England and Wales
is affected by invasive neonatal GBS disease'", Adults are known to account for
more than half of all invasive GBS cases", and it has been suggested that GBS
infection is increasing in adults, particularly those with medical disorders,
pregnant women and the elderly". There have been few studies of adults in the
UK with invasive GBS infection.
3.3 MATERIALS AND METHODS:
3.3.i Enhanced surveillance of hospitals in the Oxford region:
OBS isolates from normally sterile sites were collected for a retrospective period
from 1995 to 2000 and prospectively from March 2000 to September 2003.
3.3.i.a Retrospective study, John Radcliffe and Horton Hospitals,
Microbiology Laboratories. The retrospective collection of isolates was
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assembled by interrogation of the laboratory computer databases of freezer files.
Isolates were retrieved from freezer vials (Tryptone-soy broth with glycerol)
being stored at -80°C.
3.3.i.b Prospective study: John Radcliffe Hospital and Hospitals in the
Oxford region. The microbiology laboratory at the John Radcliffe
hospital (JRH) was the host laboratory. Medical microbiologists and biomedical
scientists were made aware of the study. In addition, weekly computer alerts
were printed out listing all the group B streptococci isolated from normally
sterile sites over that week.
Consultant microbiologists from the hospitals within the Oxford region were
informed by telephone, by post and by means of a presentation at the regional
microbiology meeting "the bug club" of the group B streptococcal research in
progress in Oxford. The microbiologists were asked to send every group B
streptococcal organism isolated in their laboratory to the research laboratory at
Oxford. They were asked to fill in a brief form to accompany the isolates (Figure
3.1). The microbiology departments taking part were from the hospitals in
Banbury, Bedford, Kettering, Luton, Milton Keynes, Northampton, Reading,
Aylesbury, Slough and High Wycombe. The participating departments were
informed of results and encouraged to continue taking part by means of a
biannual newsletter (Figure 3.2) and by regular presentations at the "bug club".
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Figure 3.1: GBS invasive infection form to accompany isolates sent to the study
laboratory .
GROUP B STREPTOCOCCAL STUDY
Dr Nicola Jones
Research Lab
John Radcliffe Hospital level 7
Oxford OX3 9DU
Group B streptococcus has been isolated:-
• Specimen type: Blood! CSF! Joint asp! Bone! Other (please state)
• Date of specimen
• Hospital where GBS was isolated
• Micro lab number
• Name of patient or initials
• Patient's hospital number
• Patient's date of birth
• Brief clinical details
Any comments:
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Figure 3.2: GBS newsletter circulated to Microbiology Consortium six monthly.
1st February 2002
GBS NEWSLETTER
DEPARTMENT OF MICROBIOLOGY
JOHN RADCLIFFE HOSPITAL
OXFORD 0X3 9DU
GBSCARRlAGESTuDY
HORTON HOSPITALACTI·N
RESEARCH Action Research has funded a carriage
study at the Horton Hospital and JR
Hospital Maternity Units. This study has
now started and is expected to run for a
further 6 months.
GROUP BSTREPTOCOCCALSTUDY
Invasive disease
Thank you for participating in this study and
sending isolates of GBS from normally sterile
sites, including blood, CSF and joint fluids.
Over the page is a breakdown of the figures
since 1st April200l until 31st January 2002.
Tire study is on going, so please continue to
send any isolates to tire lab in.
This project is funded by the MRC.
GBS READING .......
National Interest: "Confirmed group B streptococcus infection: the tip of the iceberg". Estimated
neonatal GBS infection rates from St George's Hospital, London are 2.6/1000 live births. Bedford
Russell A et a!. Arch Dis Child Fetal Neonatal Ed 2001; 84: F 140.
Microbiology: "Use of GBS media for rapid detection of Group B streptococcus in vaginal and
rectal swabs from women in labour". GBS broth and plates (Islam - type media) were compared to
CDC recommended techniques for isolation ofGBS. Further study is needed. Votava M et a!. Eur J
C1inMicrobiol Infect Dis 2001; 20: 120-22.
Carriage studies: "Group B streptococcus colonisation in male and non- pregnant female
university students". One third of college students were carrying GBS in GU/ rectal sites. Carriage
persisted for 6 months in the vast majority. Bliss SJ et a!. Clin Infect Dis 2002; 34: 184-90.
Prevention: "Group B streptococcal disease. From trials and tribulations to triumph and
trepidation". Review article of preventative strategies adopted in USA and their results. Potential
and actual adverse effects associated with such strategies are also covered. Schuchat A. Clin Infect
Dis 2001; 33: 751-6.
From Dr Nicola Jones (specialist registrar microbiology, Oxford)
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3.3.;; Microbiological handling of isolates:
Isolates received in the laboratory were plated onto Colombia agar with 5%
horse blood then incubated overnight at 37°C in a CO2 enriched (5%)
environment. Colonies were then confirmed as GBS according to the methods
described in Chapter 2.
3.3.;;i Database of clinical information:
A Microsoft Access database was developed. Details listed were the patient's
initials, date of birth, specimen type, date of collection of isolates. brief details of
diagnosis and referring hospital.
3.3.iv Calculation of incidence figures:
Incidence figures were calculated using data from the hospitals within
Oxfordshire (the JRH, Oxford and Horton Hospital, Banbury) only. Data
covering three-years from September 2000 to September 2003, within the
prospective study period, were used. The 200 I census
(http://www.statistics.gov.uk) was used as the source of population numbers in
age groups in Oxfordshire. Adult incidence was expressed as cases per 100,000
population per year. Neonatal incidence figures for invasive GBS disease were
expressed as figures per 1000 live births. Birth rates were supplied by the
Maternity Units, John Radcliffe and Horton Hospitals.
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3.4 RESULTS:
The enhanced surveillance project resulted in a collection of 299 cases of
invasive GBS (Table 3.1). Seventy-six cases were identified by the retrospective
study (1995-2000), from freezer files of organisms kept at the John Radcliffe (66
cases) and Horton Hospitals (10 cases). The remainder (223 cases) were
identified prospectively from the Hospitals within the Oxford region.
Table 3.1: GBS invasive disease: numbers of cases according to hospital and age
group.
Hospital Neonate Neonate Child 90 days Adult Adult TOTALS<7 days 7-90 days - 16 years 16-59 years >60 years
Oxford 27 15 6 46 (20)* 46 (II )** 140
Aylesbury 5 2 0 2 (2) 1 (0) 10
Banbury 8 2 0 I (0) 4 (2) 15
Bedford 6 3 I 4 (4) 6 (2) 20
High Wycombe 5 0 0 8 (6) 7 (2) 20
Kettering 3 2 0 4 (0) 7 (I) 16
Luton 4 5 0 4 (3) 4 (I) 17
Milton Keynes 3 I 0 2 (I) 0(0) 6
Northampton I I 0 2 (2) 0(0) 4
Reading 6 10 0 3 (2) 10 (4) 29
Slough 3 2 0 8 (2) 9 (4) 22
TOTALS 71 43 7 84 (42) 94 (23) 299
Numbers in parentheses are cases of invasive GBS disease in *adult females 16-
44 years and ** adults over 80 years.
The distribution of invasive GBS infection according to age group for the entire
population is illustrated graphically in Figure 3.3.
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Figure 3.3: Invasive disease due to GBS according to age group (n=299).
neonatal
Adult >60y:
94(32%)
neonatal 7-90
days: 43(14%)
Adult 16-59y:
84(28%)
Child 90 days -
16 years:
7 (2%)
It can be seen that approximately one-third of cases were found in neonates,
with early-onset disease accounting for slightly more than late-onset. Sixty
percent of infections affected adults, with roughly equal numbers being less than
60 years and over 60 years of age. The age distribution at onset of infection is
shown for neonates in Figure 3.4 a and b.
Clinical diagnosis is indicated in Figure 3.5 for the Oxford population.
Diagnoses were determined for all neonatal cases and is shown in Figures 3.6 a
and b for early and late-onset neonatal disease.
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Figure 3.4: Age at onset for cases of early onset (n=71), (a) and late (n=43) (b)
onset GBS neonatal disease.
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Figure 3.5: Diagnoses associated with invasive GBS disease in all age groups
(n=140). Figures are number (%); 25 had more than one diagnosis.
Osteoartic.
9(5%)
Puerperal
sepsis
4(2%)
IE
Pneumonia
11(7%)
UTI
2(1%)
Meningitis
23(14%) Bacteraem ia
114(70%)
Figure 3.6: Clinical diagnosis of neonatal invasive GBS for early onset (n=71)
(a) and late onset (n=43) (b) infection.
Pneumonia
Osteoartic. 5 (6%)
1(1%)
(a)
Osteoartic.
3(5%)
(b)
Meningitis
12(21%)
Bacteraemia
65 (82%)
Figures are number (%). More than one diagnosis was recorded for 9 early and
14 late cases.
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The calculated incidences (Table 3.2) ofGBS invasive disease affecting adults in
the Oxfordshire region in different age groups showed the highest incidence to
be in adults over 60 years (6.1/100,0001 year).
Table 3.2: Incidence of adult GBS infection, according to age group from
September 2000-2003.
A~e No. cases Population" Incidence +
Adult 16-59 years 22 379,065 1.9
Adult >60 years 21 115,349 6.1
Overall 43 494,414 2.9
* Population of Oxfordshire from 2001 census (http://www.statistics.gov.uk)
+ incidence: cases of invasive GBS disease per 100,000 population in that age
groupl year.
The birth cohort for the period September 2000-2003 at the JRH was 22,275 live
births (Table 3.3). The calculated incidence of neonatal GBS infection was
0.9411000 live births overall, with 0.63/1000, early-onset and 0.31/1000, late-
onset. Using the birth cohort as the number of pregnant women, the incidence of
cases of GBS infection in pregnant women was calculated as 18.0/100,000.
Table 3.3: Incidence of neonatal GBS infection, early and late onset in
Oxfordshire September 2000-2003.
Neonatal GBS No. cases Birth cohort Incidence*
Early-onset 14 22275 0.63
Late-onset 7 22275 0.31
Both 21 22275 0.94
*Incidence, cases of invasive GBS disease per 1000 live births
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Case record review was carried out for all neonates with GBS disease admitted
to the JRH. Thirty-four of 42 case records could be retrieved. Maternal risk
factors for neonatal GBS disease were identified in 13 of 25 cases of early onset
infection. The occurrence of risk factors is shown in Table 3.4. Twenty-three
complications were seen in 34 cases of neonatal GBS infection, which are listed
(Table 3.5). Four cases (11.8%) proved to be fatal. Surface swabs were taken
from 17 neonates with early onset GBS disease. GBS was isolated most
frequently from ear and throat cultures (Figure 3.7).
Table 3.4: Risk factors identified in the mothers of25 cases of early onset
neonatal GBS disease.
Risk factor: Number of cases (%)
No identified risk factor 12 (48)
Prolonged rupture of membranes 5 (20)
Prematurity «37 weeks) 4 (16)
Fever (>38°C) 3 (12)
PROM, prematurity I (4)
PROM, fever 2 (8)
PROM, fever, prematurity I (4)
Abbreviations: PROM, prolonged rupture of membranes> 18 hours.
Table 3.5: Clinical manifestations recorded in 34 cases of neonatal GBS disease
(early and late onset).
Clinical manifestation: Number of cases
Respiratory failure 6
Seizures 5
Coagulopathv 3
Severe liver impairment 2
Acute renal failure 1
Hydrocephalus 1
Intraventricular haemorrhage 1
Fatal outcome 4
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Figure 3.7: Surface swab cultures from neonates (n=17) with early onset GBS
infection. Positive results at each site are recorded as %.
throat
44%
umbilicus nose
3% 8%
ear
45%
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3.5 DISCUSSION:
Almost 300 isolates from cases of invasive GBS disease were collected over
eight years, both retrospectively and prospectively. Incidence rates ofGBS
invasive infection were calculated for Oxfordshire using 2001 census figures and
live birth rates.
3.5.i NeonatalGBS incidencerates:
The overall incidence of neonatal GBS infection in Oxfordshire was 0.9411000
live births, of which 67% were cases of early-onset infection. These incidence
rates are similar to those found in previous studies in the UK. In particular the
incidence of early-onset GBS infection was found to be 0.5/1000 in 1998 in
Oxford'", 0.95/1000 in 1998 in Sunderland" and 0.5/1000 in the UK national
surveillance study'", The finding that approximately two-thirds of cases are early
in onset is consistent with the results of other studies'".
3.5.ii Adult GBS incidencerates:
Incidence of invasive GBS infection has not been well studied. Most of the
available data comes from North America. where incidence rates of 4.1 to
7.2/100,000 have been described". In a Canadian study, 41/100,000 pregnant
women were diagnosed with invasive GBS infection compared with 4.1/100,000
in non-pregnant women'". An investigation of people over the age of 65 years
gave incidence rates of 17.5/100,000 ofGBS invasive infection in those over 65
years living in the community, compared with 72.3/100,000 in those living in
nursing homes". The incidence rates in Oxfordshire are somewhat lower than
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these figures, with 2.9/100,000 people over the age of 60 years having invasive
GBS infection per year. The ratio of approximately half the infections occurring
in the age group under 60 years and half occurring after 65 years, is however,
maintained.
Age distribution of cases shows that approximately one-third of cases of
invasive GBS occur in neonates and the remainder in adults. Almost 50% of
early onset neonatal cases occur in the first 24 hours. This is consistent with the
findings of other studies?". Clinical diagnoses associated with invasive GBS
disease were predominantly bacteraemia with no focus and then meningitis. This
was found when the entire population was studied and was also the case when
neonates were studied in isolation.
Case record review for 34 neonates with GBS disease admitted to the JRH
showed that maternal risk factors were not present in approximately 50% of
cases. Complications ofGBS disease occurred commonly in neonates, with
respiratory failure and seizures being most prevalent. The neonatal mortality rate
was 11%, which approximates with national published figures'". Surface swabs
taken from neonates with early onset infection showed that GBS was cultured
most frequently from ear and throat sites, which has been previously
demonstrated 140.
In conclusion, a large collection of GBS isolated from cases of invasive infection
in all age groups has been assembled for further study using MLST. Incidence
rates of infection have been calculated. Age distribution and diagnoses
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associated with infection have been described. More detailed review of neonatal
case records has given some information about risk factors for infection,
complications of infection and mortality rates.
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Chapter 4: Asymptomatic Carriage of GBS in Pregnant
Women from Oxford, UK.
4.1 AIMS:
1. To undertake a carriage study in Oxfordshire of GBS carriage rates in
pregnant women.
2. To determine risk factors for carriage.
3. To assemble a collection of carried isolates ofGBS from pregnant
women for molecular epidemiological study.
4.2 INTRODUCTION:
GBS is the leading cause of neonatal sepsis in many parts of the world including
the UK65• Administration of lAP to the GBS colonised woman is an effective
strategy for the prevention of early-onset neonatal sepsis'". The Royal College of
Obstetricians (http://www.rcog.org.uk), and the Health Protection Agency
(formerly PHLS) (http://www.hpa.org.uk) have published draft and interim
guidelines for the prevention of neonatal GBS infection in the UK that
recommend the identification of risk factors 108 in the mother to guide
administration ofIAP. The CDC have recommended universal screening in the
USA to identify GBS carriers who will then receive IAp66•
The development of national guidelines for prevention of neonatal GBS has been
hampered in the UK by a lack of epidemiological data. The investigations that
have been carried out have given different results. A study carried out in London
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in 1987 identified a carriage rate ofGBS of28% in pregnant women", whereas
results a study in North Wales (2001) detected a much lower rate of 4.3%34.An
investigation carried out in the Republic ofIreland (1998) was more akin to the
London study, showing a 25.6% carriage rate'".
4.3 MATERIALS AND METHODS:
A prospective carriage study was carried out in the Oxford area of the UK over a
2-year period (2001-3). Pregnant women attending antenatal care at hospital and
community units attached to the JRH, Oxford, and at the Horton Hospital,
Banbury were recruited. A single vagino-rectal swab for culture of GBS was
taken from participants. Questionnaires (Figure 4.1 and Figure 4.2) were used to
gather demographic and epidemiological data about the pregnancies and
outcomes for women attending the Horton Hospital. No data were collected from
women attending the JRH other than GBS carriage status. Local policy was
followed to guide the administration ofIAP. The Oxfordshire Ethics Committee
granted ethical approval (COO.035,Appendix 2).
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Figure 4.1: Questionnaire for recruited pregnant woman to complete.
PREVENTING INFECTIONS IN THE NEWBORN BABY
THE HORTON HOSPITAL GBS CARRIAGE STUDY
confidential questionnaire for patient
Please tick Yes/No boxes andjill in the large boxes.
1. How many weeks pregnant are you? D
o No oHave you ever been Pregnant before? Yes2.
If Yes, How many times? D
o No o3. Have you taken antibiotics in the last three months? Yes
If yes, can you tell us what they were _
and what they were for? _
4. Which ethnic group do you consider yourself to belong to?
White - Irish0 Any other White background 0White - British 0
Mixed- White and Black Caribbean 0 Mixed - White and Black African 0
Mixed - White and Asian0
Black- Caribbean 0 Black-African 0
Any other Mixed backgound 0
Any other Black background 0
Pakistani 0 Indian 0 Bangladeshi 0 Chinese 0 Any other Asian background 0
Any other Ethnic group 0 Do not want to give ethnic group0
5. Are you married or living with someone? 0 Or single/ widowed! divorced? 0
6. What job do you/ did you do most recently? _
7. If you are married or living with someone what job does your partner do? _
attach sticky GP details attach stickyName
DOB
Hosp no
Address
Name
Surgery
Thank you very much for completing this questionnaire. Please hand it to the midwife as soon as
possible. Any other comments?
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Figure 4.2: Questionnaire for Midwife in attendance to complete.
PREVENTING INFECTIONS IN THE NEWBORN BABf
THE HORTON HOSPITAL GBS CARRIAGE STUDY
Confidential Questionnaire for Midwife to complete
To be completed after the birth a/the baby.
Please tick Yes/ No boxes
Patient's name
DOB
Hosp no
Address
Or patient's sticky
1. Please fill in details for the baby: Male0 Female 0 Weight (g) _
2. Date of delivery .1 1 .
3. Has GSS been isolated from the mother during pregnancy? No 0
Yes 0
If Yes, please ring site where GSS was isolated urinel vaginal blood! placenta
Method of delivery: Spontaneous vaginal
Ventouse extraction
Forceps
Caesarean section- emergency
- elective
ooooo
4.
Other
5. Did complications develop in the mother? No
(Only during labour) Yes
Ogoto Q6o
If yes, please give details: 0 Fever> 38 degC
Prolonged rupture of membranes >18 hours
Premature delivery « 37 weeks), at weeks
Other _
Were antibiotics given to the mother during labour? No
Yes
oo6.
If yes which antibiotic............... PO0
IV 0
Given> 4 hours or less than 4 hours
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Women were recruited in the antenatal clinic, and a single vagino-rectal swab (a
sweep with a swab from low vagina down the perineum to just inside the
rectum) was then taken when the woman presented to the hospital in labour. The
swabs were handled in the research microbiology laboratory at the JRH
according to an algorithm (Figure 4.3) based upon standard methods'". Swabs
were cultured overnight at 37°C in 20 ml vials of Todd-Hewitt Broth containing
gentamicin Smg/L and nalidixic acid 15 mg/L 66 then plated out onto Columbia
agar with 5% horse-blood for overnight culture in CO2 at 37°C. ~-haemolytic
colonies, which were negative with catalase reagent, were further investigated by
Gram-staining and culture on BAA14l. Colonies growing on BAA without black
pigment production were confirmed as GBS by Gram-staining and detection of
Lancefield group B antigen by latex agglutination (Oxoid, Basingstoke, UK).
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Figure 4.3: Algorithm for laboratory handling of vagi no-rectal swabs, isolation
and identification of GBS.
Sample Collection
Vagino-rectal swab in Amies Charcoal transport medium
Transport to Laboratory
H
Broth-enrichment culture
Swab placed in Todd-Hewitt broth with gentamicin and
nalidixic acid
H
Overnight culture, 37°C
Culture broth on Blood Agar
Loopful of broth culture is plated onto 5% blood agar
Overnight culture, 37°C
8- haemolytic colonies
Catalase- negative
I
Gram-positive cocci in
pairs or short chains
Gram-stain
Bile-aesculin agar culture
Colony streaked onto BAA
\
I \ 4-hour culture,37°C
I
Growth,no
pigment
Black
pigment
Lancefield Group B Antigen
Latex Agglutination Test
+ Discard:
not GBS
II Group B Streptococcus II
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4.4 RESULTS:
Seven hundred and forty eight women were recruited over two years (2001-3),
of which 167 were from the Horton Hospital, Banbury and the remainder from
the JRH, Oxford. One hundred and fifty-nine women (21.3%) were carriers of
GBS. There was no significant difference between carriage rates at the JRH, a
tertiary referral hospital, and at the Horton which is a district general hospital.
4.4.i Results of demographic and clinical questionnaires:
For the 167 mothers recruited at the Horton Hospital, further data were available
from questionnaires. The demographics of the study population showed that
92.8% of the pregnant women were white-British (Table 4.1) and 91.0% were
married (Figure 4.4). First-time pregnancies made up 45% of recruited women
(Figure 4.5). There were 170 infants born to 167 women, of which 93 (54.7%)
were female.
Table 4.1: GBS carriage study: Ethnic origin of pregnant women at the Horton
Hospital.
Ethnic origin Number(%)
British-white 155 (92.8)
Other-white 7 (4.2)
Asian-other 2 (1.2)
African ) (0.6)
Irish-white ) (0.61
Pakistani ) (0.6)
Total 167
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Figure 4.4: GBS carriage study: Marital status of pregnant women at the Horton
Hospital.
Divorced 1%
Cohabiting 3%
Single 4%---..
Married
91%
Figure 4.5: GBS carriage study: number of pregnancy at time of study in
pregnant women at the Horton Hospital.
5th 6th
3rd
13%
1st
44%
32%
Twenty-six women (15.6%) recalled receiving oral antibiotics at some time
during their pregnancy (Table 4.2). Approximately 50% of women could not
recall why they were treated and what the antibiotic was called. Of those who
could remember, urinary sepsis was the most frequent reason and amoxicillin or
cephalexin was commonly given. Only 1 of the 26 cases receiving oral
antibiotics was carrying GBS vagino-rectally, Eight women had GBS isolated
from vaginal swab culture, carried out incidentally during their pregnancy. Only
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one of these eight women proved to be carrying GBS at delivery on vagino-
rectal sampling. Three of the 8 cases had received oral antibiotics during
pregnancy.
Table 4.2 : GBS carriage study: oral antibiotics (PO) given during pregnancy
and reason for course of antibiotics.
Reason for antibiotic course Antibiotics 2iven (PO)
UTI 9 Amoxicillin 6
ROM 1 Cephalexin 6
Chest infection 2 Erythromycin 2
Do not remember 14 Penicillin I
Do not remember 11
Total 26 Total 26
Abbreviations: UTI, urinary tract infection; ROM, rupture of membranes; PO,
per oral.
4.4.;; Results of screeningfor GBS with vagino-rectalswab culture:
Twenty-nine mothers (17.4%) from the Horton Hospital were GBS carriers. In
34 (20.4%) mothers a risk factor (fever>38°C, prolonged rupture of membranes
>18 hours, pre-term delivery <37 weeks) for GBS colonisation was idcntified"
(Table 4.3). The correlation between GBS carrier status and identification of a
risk factor was not significant (Table 4.3). GBS carrier status was not
significantly associated with any risk factor and 24 women with GBS did not
develop a risk factor. Twenty-five percent of women would have been treated
with lAP in this study using the risk factor approach and a minimum of 21%
under the screening approach (CDC guidelines").
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Table 4.3: The occurrence of risk factors during pregnancy, with level of
significance, in women attending the Horton Hospital.
GBS carrier GBS negative p, value* Odds ratios
(n=29) (n=138) (95% Cl)
Instrumental I CS delivery 7 50 0.3 0.6 (0.2-1.5)
Any risk factor 5 29 0.8 0.8 (0.2-2.4)
Fever>38°C 2 9 0.6 1.1 (0-5.8)
PROM> 18hours 2 14 0.5 1.1 (0-5.8)
Preterm <37 weeks 0 3 0.6 0(0-11 )
Fever and PROM 1 3 0.5 1.6 (0.3-3.8)
Abbreviations: Cl, 95% confidence intervals; CS, caesarean section; PROM,
prolonged rupture of membranes
* Yates-corrected test used, except where values were <5, then one-tailed Fisher
exact test used.
Twelve women (7.2%) were given intravenous antibiotics (coamoxiclav,
amoxicillin or cefuroxime) during labour. The indication for antibiotic therapy
was emergency CS in four cases, two each had fever or prolonged rupture of
membranes, one had premature delivery and for 3 cases, the indication was not
recorded. The rate of instrumental delivery was 34.1% overall, and was not
significantly affected by GBS carrier status.
A single case of early onset GBS neonatal infection occurred in the study period
in a premature infant born at 34 weeks to a mother who had not, for logistic
reasons been recruited to the study.
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4.5 DISCUSSION:
The carriage rate of GBS in pregnant women in the Oxford area is 21.3%. This
is a similar rate to that seen in London in 1987 and in Ireland in 1991, but is
considerably higher than that seen in North Wales 2002. The methodology used
in the North Wales study was similar to that used in this study, vagino-rectal
swabs were taken from pregnant women and cultured in selective broth culture.
This suggests that geographical variation in GBS carriage rates may be large in
the UK. Possible causes for this variation may be socio-economic, due to local
patterns of antibiotic use and may be affected by ethnicity of the population in
question.
The Horton Hospital, Banbury is a small district general hospital in rural
Oxfordshire. This site was chosen as the focus for a questionnaire based
epidemiological study of GBS carriage as it is not a tertiary referral unit, in order
to avoid a bias towards complicated and high-risk pregnancy in the study. The
carriage rate ofGBS (17.4%) at the Horton Hospital was not significantly
different from that found at the JRH (22.4%).
Demographic questions were included in a questionnaire and were filled in by
recruited pregnant women. The demographic profile of the population of women
attending the Horton Hospital was not cosmopolitan, the vast majority of women
being married and ethnically white-British.
Antibiotic use during pregnancy was fairly common, with 15.6% of women
recalling recent oral antibiotic use. The fact that the majority of women could
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not recall why or with what drug they had been treated suggests that education of
the pregnant woman or the wording of the questionnaire may need to be
improved. Of the 8 women who had incidentally had a previous vaginal culture
showing OBS, three had received a course of oral antibiotics and only one had a
positive culture at delivery. This provides support for the assertion that OBS
carriage can be dynamic and that cultures taken within four weeks of delivery
are most predictive ofOBS carriage status at delivery.
During 2001-3, there were II cases of early onset OBS infection admitted to the
JRH in a birth cohort of 12032, giving a rate of 0.9/1000 live births. This is in
keeping with a previous study of neonatal invasive OBS disease in Oxford'".
An important finding was the poor correlation between OBS carriage and the
development of risk factors in the studied women. Approximately the same
number of women would be treated with antibiotics according to this study
under the risk factors based or the screening approach. It is difficult therefore to
recommend the risk factor approach over the screening method given that the
same numbers of women are likely to be treated with lAP according to both
strategies; however, with a lower efficacy of the risk factor approach in the
prevention of OBS neonatal disease.
In conclusion, in this UK study of 748 pregnant women, 21.3% were colonised
vagino-rectally with OBS. Epidemiological data were collected for a subset of
167 women. Colonisation by GBS was not significantly associated with the
previously published risk factors, such as fever, prolonged rupture of membranes
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and preterm delivery, although the numbers in each group were small. Twenty-
four percent of women would have been given with lAP should a risk-factor
strategy be followed and 21% would have received lAP if a screening policy
was adopted.
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Chapter 5: Development of a Multilocus Sequence
Typing System for Group B Streptococcus
5.1 AIMS:
I. To determine suitable genes for use in the OBS MLST system.
2. To design oligonucleotide primers that are reliable in amplification and
sequence analysis.
3. To optimise peR and sequence reactions.
5.2 INTRODUCTION:
Investigation of the epidemiology of infectious diseases is dependant on the
ability to characterise strains of a bacterial pathogen. MLST was proposed in
1998124as a general approach to provide accurate and portable data suitable for
such study. Recombination is common in populations of many bacteria.
Furthermore, areas of the chromosome, where evolution is likely to be rapid and
under strong selection pressure will probably be most variable and least suitable
for determining the population structure of the species. Housekeeping genes, that
is those coding for proteins of essential metabolic functions in the cell, are
functionally constrained, not under strong selective pressure and the variation
that accumulates in these genes is therefore likely to be neutral. Housekeeping
genes, flanked by genes of similar function, are consequently good targets for
MLST systems 125. Most of the MLST systems that have been developed utilise
450 to 500 base-pair fragments of seven genesI24.134.142.143.The elements that are
critical in the development ofa system ofMLST and which are the focus of this
study, include the choice of genetic loci to be characterised and the design of
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oligonucleotide primers for gene amplification and nucleotide sequence
determ ination 125.
5.3 MATERIALS ANDMETHODS:
5.3.i Assembly of collection of isolates:
A small collection (n= I0) of GBS isolates was assembled for the development of
the MLST procedure. The isolates were acquired from cases of invasive GBS
disease (n=6) and asymptomatic carriage (n=4) from the United Kingdom and
Asia.
5.3.;; Development of Oligonucleotideprimers:
Twelve genes were chosen for study. The genes were those responsible for
essential cell metabolism, where variation within the population was presumed
to be selectively neutral and the majority had been successfully utilised in MLST
of other bacterial pathogens. The NEM316 GBS genome 144 was screened using
homologous sequences of selected housekeeping genes from other organisms in
order to obtain the GBS sequence of the studied genes. Oligonucleotide primers
were then designed from these GBS sequences.
5.3.ii.a Candidate genes. The genes studied were the following:- pgm,
phosphoglucomutase (gbs0904); purK, phosphoribosylglycinamide
formyltransferase (gbs0003); pscB, ribose-phosphate pyrophosphokinase
(gbs0017); cysK, cysteine synthetase A (gbs0323); ribF, riboflavin biosynthesis
protein (gbsl032); adhP, alcohol dehydrogenase (gbs0054);pheS, phenylalanyl
tRNA synthetase; atr, amino acid transporter (gbs0538); ginA, glutamine
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synthetase; sdhA, serine dehydratase (gbs2105); glcK, glucose kinase (gbs05IS);
tkt, transketolase (gbs2105).
5.3.ii.b Oligonucleotide primer design. A nested method was designed
utilising 2 sets of primers. The first set of primers were used in the peR reaction
and amplified a large fragment (700 bp) of DNA, the second set of primers were
located inside the first set and were used for sequencing, resulting in a sequenced
region of about 500 bp of DNA.
The DNA sequences of the study genes were analysed by eye, to detect potential
areas with suitable GC content (approaching 50%) for primer design. Runs of20
base-pairs of DNA within the study genes, to result in an amplicon of suitable
size, were entered into the internet based oligonucleotide properties calculator
(http://www.basic.nwu.edulbiotools/oligocalc.html) for calculation of melting
temperature, GC content and the presence of secondary structure associated with
reduced efficiency of priming. Primers with favourable qualities were tested
against the collection ofGBS isolates. If amplification or sequencing were not
reliable, then different combinations of primers or new primers were then tested.
From the panel of twelve genes, seven were chosen to make up the GBS MLST
system. To determine which genes would be used in the final system, the
following factors were considered. Firstly, the diversity of the genes, as
measured by the number of different sequences (alleles) identified for that gene,
dr/ds ratios and the factor 1t, a measure of nucleotide diversity. Secondly, the
genes were grouped together into three groups, group I (adhP, pheS, atri; group
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2 (gInA, sdM, glcK, tkt) and group 3 (pgm, ribF, pscB. cysK). Sequences were
concatenated and then trees were generated (using UPOMA) for different
combinations of groups (groups 1+2, groups 1+3 and groups 2+3) and analysed
for tree morphology, which most closely approximated that when all genes were
included.
5,4 RESULTS:
Twelve genes were successfully amplified in peR reactions and sequenced. In
the case of the purK gene, only 300 base-pairs could be successfully sequenced.
The sequences of the primers are listed in Table 5.1.
Table 5.1: Oligonucleotide nucleotide primers utilised in the MLST system for
OBS.
Name and Sequence of Oligonucleotide Primer
Locus Forward (5' to 3') Reverse (5' to 3') Amplicon
size (bp)
adhP ampl ification GTTGGTCATGGTGAAGCACT ACTGTACCTCCAGCACGAAC 672
sequencing GGTGTGTGCCATACTGATTT ACAGCAGTCACAACCACTCC 498
pheS amplification GATTAAGGAGTAGTGGCACG TTGAGATCGCCCATTGAAAT 723
sequencing ATATCAACTCAAGAAAAGCT TGATGGAATTGATGGCTATG 501
atr ampl ification CGATTCTCTCAGCTTTGTTA AAGAAA TCTCTTGTGCGG AT 627
sequencing ATGGTTGAGCCAATTATTTC CCTTGCTCAACAATAATGCC 501
ginA amplification CCGGCTACAGATGAACAATT CTGATAATTGCCATTCCACG 589
sequencing AATAAAGCAATGTTTGATGG GCATTGTTCCCTTCATTATC 498
sdhA amplification AGAGCAAGCTAATAGCCAAC ATATCAGCAGCAACAAGTGC 646
sequencing AACATAGCAGAGCTCATGAT GGGACTTCAACTAAACCTGC 519
XlcK amplification CTCGGAGGAACGACCATTAA CTTGTAACAGTATCACCGTT 607
sequencing GGTATCTTGACGCTTGAGGG ATCGCTGCTTTAATGGCAGA 459
tkt ampl ification CCAGGCTTTGATTTAGTTGA AATAGCTTGTTGGCTTGAAA 859
sequencing ACACTTCATGGTGATGGTTG TGACCTAGGTCATGAGCTTT 480
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The characteristics of the studied genes are listed in Table 5.3. The gene,purK,
which was not reliably sequenced for 500bp and showed a much higher diversity
was excluded from further analyses. The remaining genes were similar in their
amount of diversity.
Table 5.3: Measures of diversity in candidate genes utilised in the development
ofMLST for GBS.
Gene No. Synonymous Non- No. %GC 1[
Segregating base changes Synonymous alleles
Sites base changes
adhP 8 5 3 6 0.43 0.0063
pheS 5 4 1 3 0.37 0.0067
atr 9 6 3 6 0.37 0.0076
ginA 4 4 0 3 0.36 0.0054
sdhA 11 8 3 4 0.42 0.012
f[lcK 5 4 1 3 0.43 0.0073
tkt 5 2 3 3 0.39 0.0069
pgm 3 0 3 2 0.38 0.0066
ribF 3 3 0 2 0.36 0.0071
'purK 33 25 8 4 0.51 0.044
'pscB 3 0 3 3 0.37 0.004
cysK 4 1 3 2 0.4 0.0078
Trees generated (Figure 5.1) from the 3 groups of genes suggested that the
combination of group 1 (adhP, pheS, atr) and group 2 (gInA, sdhA, glcK, tkt)
resulted in a tree which more closely approximated the tree generated with the
sequences of all 11 genes. In addition, it was noted that ribF, cysK, pgm had
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fewer alleles and that pscB had the lowest value for n, as support for their
exclusion.
Figure 5.1: Trees generated using UPGMA of 10GBS isolates based upon the
concatenated nucleotide sequences of fragments of seven to twelve genes.
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The system was then based upon the 7 genes from groups 1 and 2, adhP, pheS,
atr, gInA, sdhA, glcK, tkt. The location of these genes around the GBS
chromosome is pictured in Figure 5.2, the minimum distance between any two
genes was 20 kilo base- pairs.
Figure 5.2: Location of genes selected for MLST around the GBS chromosome.
The 2,211 ,48S-bp genome is divided into 22 segments (indicated on the inner
circle), with each segment representing 100,522 bp.
adhP sdhA
atr
ginA
f!lcK
piuS
Temperature gradient peR was carried out on the seven genes to optimise the
annealing temperature that provided a single amplified fragment in good yield.
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The annealing temperature was varied between 45 and 65°e. Figure 5.3
demonstrates a photograph of an agarose gel (1%) with the peR products of two
genes, ginA and tkt, with different annealing temperatures. It can be seen that at
61.8°e, the peR product band has become fainter, particularly in the case of tkt.
An annealing temperature of 55°e was selected, ensuring a good amount of peR
product, but high enough to be stringent and low enough to result in successful
peR in most isolates.
Figure 5.3: Photograph of 1% agarose gel labelled with ethidium bromide
showing the peR products of two genes (gInA and tkt) when peR was carried
out with annealing temperatures from 45 to 65°e.
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5.5 DISCUSSION:
The MLST was developed for GBS following the principles established
previously'<. Housekeeping genes, which had been successfully utilised for
other organisms were chosen for further study. The system developed was then
based upon seven genes, chosen for the favourable characteristics of reliable
amplification, adequate diversity and clustering by UPGMA.
The genes utilised for the MLST method were distributed around the GBS
chromosome suggesting that they were unlikely to be linked genetically in a
single recombinational event.
A nested system was followed, with different oligonucleotide primers being used
for peR and sequencing reactions in order to minimise the likelihood of non-
specific sequencing. Gradient peR reactions were carried out which determined
that amplification occurred for all genes at a range of temperatures of up to
60°C. An annealing temperature of 55°e was chosen, as a compromise between
successful peR in a large number of isolates and reducing the likelihood of non-
specific binding.
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Chapter 6: Validation and assessment ofGBS MLST as
a typing system.
This chapter has been presented in part as a poster presentation at the XV
Lancefield International Symposium of Streptococcal Diseases, Goa, India, 6- II
October 2002; session P 4.30.
This chapter has been published as:
Jones, N., Bohnsack, J.F., Takahashi, S., Oliver, K.A., Chan, M.S., Kunst, F.,
Glaser, P., Rusniok, C., Crook, D.W.M., Harding, R.M., Bisharat, N., Spratt,
B.G. A Multilocus Sequence Typing System for Group B Streptococcus. Journal
of Clinical Microbiology 2003; 41(6): 2530-2536. (Appendix 3).
A: VALIDATION OF THE GBS MLST SYSTEM ON A GLOBAL
COLLECTION OF HUMAN ISOLATES.
6.1 AIMS:
To show that the MLST system developed for GBS could be used on a diverse
globally-derived collection of isolates from neonates and adults and that the
system could distinguish between strains that were different using capsular
serotyping and RDP typing.
6.2 INTRODUCTION:
MLST developed for GBS (Chapter 5) was tested against a global collection of
human GBS isolates. The collection was intended to represent the full spectrum
of human disease and carriage. GBS was compared with two other typing
methods, capsular serotyping and restriction digest pattern typing.
73
6.3 MATERIALS ANDMETHODS:
6.3.; Assembly of collectionof isolates:
The study collection consisted of 152 isolates ofGBS from North America, New
Zealand, Thailand, Singapore, Israel, Japan and the UK. In addition two well-
characterised strains were included, the NCTC-8541 strain (isolated from
vaginal carriage, Public Health Laboratory, UK) and the NEM316 strain
(ATCC 12403, isolated from fatal neonatal sepsis, country of origin unknown),
whose genome has been fully sequenced 144. The collection was globally diverse
and included isolates from asymptomatic carriage as well as those causing
human disease. Most capsular serotypes ofGBS were represented, although
serotypes IV and VII, which are rarely associated with disease in humans, were
not included.
6.3.i; Other methods:
Methods for capsular serotyping, DNA extraction, PCR, nucleotide sequencing
and computational analyses are detailed in Chapter 2, Materials and Methods.
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6.4 RESULTS:
6.4.i Collection ofGBS isolates:
Table 6.1 further describes the isolate collection.
Table 6.1 : GBS isolate collection used for the development of MLST system.
Figures are numbers of isolates (%).
Country Neonatal Adult Totals
Carried Invasive Carried Invasive
UK 0 21 (13.9) 20(13.2) 0 41 (27.1)
USA 0 14(9.2) 6 (4.0) 2 (1.2) 22 (14.4)
Japan 0 15 (9.9) 30 (19.7) 0 45 (29.6)
New Zealand 2 (1.2) 6 (4.0) 5 (3.3) 10 (6.6) 23 (15.1)
Israel 0 0 3 (2.0) 7 (4.6) 10 (6.6)
Singapore 0 1 (0.6) 0 6 (4.0) 7 (4.6)
Thailand 0 0 3 (2.0) 0 3 (2.0)
Unknown* 0 1 (0.6) 0 0 1 (0.6)
Totals 2 (1.2) 58 (38.2) 67 (44.2) 25 (16.4) 152
* NEM316 (ATCC 12403)
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6.4.# Variation at the seven MLST loci:
The sequences of the seven chosen loci were determined for the 152 isolates and
allelic profiles assigned. The alleles defined for the MLST scheme were based
on sequence lengths of between 459 (g/cK) to 519 base pairs (sdhA). Between 4
(glcK) and 11 alleles (adhP) were present at each locus. The average number of
alleles at each locus was 6.4, providing the potential to distinguish 4.4 x 105
different genotypes. The proportion of variable nucleotide sites present in the
chosen housekeeping genes ranged from 1.2% (gInA) to 2.5% (sdhA) (Table 6.2
and Figure 6.1). The proportions of nucleotide alterations that changed the
amino acid sequence (non-synonymous substitutions, dn) and the proportions of
silent changes (synonymous substitutions, ds) were calculated for each gene.
Using this data the dt/ds ratios were calculated for all seven loci and were all <1
(Table 6.2).
Table 6.2: Characteristics of loci included in the GBS MLST system.
Locus Size of No. of No. of %GC d,lds Position in
sequenced alleles polymorphic GBS
fragment identified nucleotide sites genome
(bp) (%) (bp)144
adhP 498 11 12(2.4) 43.1 0.13 72,286
pheS 501 5 7 (l.4) 37.1 0.17 912,817
atr 501 8 12 (2.4) 36.9 0.14 560,085
ginA 498 6 6 (1.2) 35.7 0.12 1,868,862
sdhA 519 6 13 (2.5) 41.4 0.12 2,179,923
If/cK 459 4 7 (l.5) 42.6 0.13 538, 770
tkt 480 5 8 (1.7) 38.9 0.42 287,111
Abbreviations: adhP, alcohol dehydrogenase (gbs0054);pheS, phenylalanyl
tRNA synthetase; atr, amino acid transporter (gbs0538); ginA, glutamine
synthetase; sdhA, serine dehydratase (gbs2105); glcK, glucose kinase (gbs0518);
tkt, transketolase (gbs2105)
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Figure 6.1: Polymorphic nucleotide sites in GBS MLST genes.
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6.4.iii Relatedness of GBS isolates:
The 152 isolates were resolved into 29 STs, 14 of which were identified only
once (Table 6.3, Table 6.4). One hundred and one isolates (66.5% of the data
set) were represented by one of four STs, ST-1, ST-17, ST-19 and ST-23. The
most common ST (ST-17) was identified 44 times in the dataset, followed by
ST-I (21 isolates), ST-19 (20 isolates) and ST-23 (16 isolates). ST-3 was not
included in this dataset, but had been identified in a pilot study.
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Table 6.3: The collection of 152 isolates of GBS described according to ST,
country of isolation, host type, epidemiology and capsule.
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Isolate No. ST Count" Host E2ldemiolo~ Ca2suk Isolate No. ST Count" Host E2idemiolo~' Ca2sule
lSI I Is A C V UK8 17 UK N I III
ISI9 Is A I V UKIO 17 UK N I III
IS2 Is A I V UKI2 17 UK N I III
U64 J A C III UKI5 17 UK N I III
U65 J A C III UK17 17 UK N I III
U88 J A C VI UK20 17 UK N III
U89 J A C VI UK21 17 UK N III
U90 J A C VI UKI8 17 UK N I III
U92 J A C VI U21 17 USA A I III
U93 J A C VIII U22 17 USA A I III
U94 A C VIII U29 17 USA A C III
U95 A C VIII UIO 17 USA N I III
U96 J A C VIII UI7 17 USA N III
NZ14 NZ N I V UI9 17 USA N III
NZ18 NZ A C V U20 17 USA N III
NZ23 NZ A I V U27 17 USA N III
T3 T A C NT U28 17 USA N 111
ZI2 UK A C V U31 17 USA N III
Z84 UK A C V U7 17 USA N III
Z95 I UK A C V U8 17 USA N III
UK22 I UK N I IB U9 17 USA N III
IS28 2 Is A I NT UI8 17 USA N III
NZ7 2 NZ A I II U30 17 USA N III
U63 4 J A C lA U32 17 USA N III
UK6 4 UK N I lA UKII 18 UK N I III
U62 5 J A C lA U54 19 J A C III
Z78 6 UK A C IB U84 19 J A C V
un 7 J A C lA NZI 19 NZ A I III
U75 7 J N I lA NZII 19 NZ A C 1JJ
U71 7 J N I lA NZ2 19 NZ N I 1JJ
U79 8 J A C IB NZ21 19 NZ A I III
NZI9 8 NZ A I IB NZ3 19 NZ N C 111
NZ4 8 NZ A I IB UK16 19 UK A C III
A8 8 S A I NT ZIOI 19 UK A C III
ZIII 8 UK A C IB ZI17 19 UK A C 111
Z72 8 UK A C IB Z77 19 UK A C II
UK13 8 UK N I IB 8541 19 UK A C NT
ISB 9 Is A C IB Z50 19 UK A C III
U78 10 J N I IB UK7 19 UK N I III
NZI7 10 NZ A I IB UKI9 19 UK N I 111
NZ20 10 NZ A I II U55 19 USA A C III
Z73 10 UK A C IB U56 19 USA A C III
Z41 10 UK A C NT U57 19 USA A C III
A2 II S A I III U58 19 USA A C III
A3 II S A I III U59 19 USA A C III
A4 II S A I III UKI 20 UK N I III
A5 11 S A I III U53 21 N I III
A6 II S A I III lSI 22 Is A I II
U80 12 J N I IB ISI2 22 Is A C 11
U81 12 J N I IB IS9 23 Is A I III
Z69 12 UK A C IB U69 23 J A C lA
T5 13 T A C VI U70 23 J A C lA
TI 14 T A C VI U60 23 J A C III
NZI5 15 NZ A I IB NZI2 23 NZ N I lA
NZ16 15 NZ N IB NZI3 23 NZ N C lA
IS56 16 Is A lA NZ22 23 NZ A I lA
U11 17 J A C III NZ5 23 NZ N I III
U23 17 J A C 1Il NZ6 23 NZ A C lA
U25 17 A C III NZ8 23 NZ A C lA
U3 17 A C 1Il NZ9 23 NZ A I lA
U4 17 A C 1Il A7 23 S N I lA
U5 17 A C III Z81 23 UK A C lA
UI 17 N I III Z87 23 UK A C V
UI2 17 N I Jll UK14 23 UK N I lA
UB 17 N I 1Il NEM316 23 NK N I III
UI4 17 N I 1Il Z18 24 UK A C lA
UI5 17 N I III U61 25 USA N I 1Il
U2 17 N I III U86 26 J A C V
U26 17 N I 1Il U87 26 J A C V
U24 17 N I 1Il UK2 26 UK N I V
NZIO 17 NZ N I III IS31 27 Is A I III
Z34 17 UK A C III U82 28 J A C 11
Z37 17 UK A C III U83 28 J A C 11
UK3 17 UK N I III UK9 28 UK N I II
UK4 17 UK N I Jll UI6 29 J N I III
UKS 17 UK N I 1Il U85 30 J A C V
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Abbreviations: ST, sequence type; NT, non-typeable; NK, not known; A, adult;
N, neonatal; I, invasive isolate; C, carried isolate; J, Japan; UK, United
Kingdom; Is, Israel; NZ, New Zealand; T, Thailand; S, Singapore.
Table 6.4: Characteristics ofGBS isolates according to ST.
ST Allelic profile* No. Serotype (No.) Source (No.) Country of
origin (No.)
1 1, 1,2, I , 1,2.2 21 V(9). VIII(4). VI(4). AC (16). AI (3). J(lO). UK (4). Is(3).
III(2). IB(I). NT(I) NI (2) NZ (3). T(I)
2 1,1,3,1,1,2,2 2 II (1). NT (I ) AI(2) Is (1). NZ (I)
4 1,1,4,1,1,3,4 2 lA (2) AC (1). NI (I) J (1). UK (1)
5 12,1,4,1,1,3,4 1 lA (I) AC (I) J (I)
6 9,1,2,1,3,2,2 1 IB (I) AC(I) UK(I)
7 10,1,2,1,3,2,2 3 lA (3) AC (I). NI (2) J (3)
8 4,1,4,1,3,3,2 7 IB (6), NT(l) AC(4), NI(1), UK(3), NZ(2), J( 1),
AI(2) S( I)
9 8,1,4,1,3,3,2 1 IB (I) AC(I) Is( I)
10 9,1,4,1,3,3,2 5 18(3),11(1), NT(I) AC(2), NI( I), UK(2). NZ(2), J( I)
A1(2)
11 9,3.7,1,3,3.2 5 III(5) AI(5) S(5)
12 10,1,4,1,3,3,2 3 IB (3) NI(2), AC( I) J(2), UK( I)
13 11,3,4,1,3,3,2 1 VI(I) AC(I) T(1)
14 1,1,2,1,5,2,2 1 VI(1) AC(I) T(I)
15 9,1,4,1,5,3,2 2 18(2) AI( 1), NI( 1) NZ(2)
16 1,1,4,1,6,3,4 1 IA( 1) AI(l ) Is( 1)
17 2,1 , 1,2, 1, 1, 1 44 IIl(44) NI(33). AC(9), US(l6), J( 14),
AI(2) UK(l3), NZ(I)
18 3,1,1,2,1,1,1 1 JII( 1) Nl( 1) UK(l)
19 1,1,3,2,2,2,2 20 JII(17), II( 1), V( 1), AC(14), Nl(3) UK(8), NZ(5),
NT(l) AI(2), NC( 1) US(5). J(2)
20 1,2,3,2,2,2,2 1 IIl( 1) NI(l) UK(l)
21 1,9,3,2,2,2,2 1 IIl( I ) NI(I) J( I )
22 13,3,1,3,1,1,1 2 11(2) AC(I), AI(I) Is(2)
23 5,4,6,3,2,1,3 16 lA(l1). 111(4), V(l) AC(7), NI(5). NZ(7), UK(3). J(3).
Al(3). NCO) Is(l), S(I). NK( I)
24 5,4,4,3,2,3,3 1 IA( 1) AC(l) UK(l)
25 5,4,6,3,8,1,3 1 IIl( I ) NI(l) US(l)
26 1,1,5,4,1,4,6 3 V(3) AC(2), NI(l) J(2). UK( 1)
27 1,1,3,4,2,2,2 1 IIl( 1) Al( 1) Is(l )
28 1,1.3,5,2,2,2 3 11(3) AC(2), Nl( 1) J(2),UK(l)
29 2,1,1 ,8, 1,1,1 1 I1I(l ) NI( 1) J(l )
30 1,1,8,2,2,2,2 1 V(1) AC(l) J( I)
Abbreviations: see Table 6.3.
*Allelic profiles for each gene are presented in the order, adhP, pheS. atr, gInA,
sdhA, glcK, tkt.
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UPGMA was used to construct a dendrogram from the matrix of pairwise
differences between the concatenated sequences of 29 STs of all 152 isolates
(Figure 6.2). BURST grouped the isolates into 7 lineages (Table 6.5), which
approximated well with the clusters ofSTs obtained by UPGMA. Split
decomposition, using concatenated sequences was also used to analyse the
relationships between STs (Figure 6.3). A naming system for complexes ofSTs
was adopted. Each complex was named after the central ST identified by
BURST. If only 2 STs were identified in a complex, then that complex was
named after the ST. which was most prevalent. In general. the three methods
clustered the STs into the same seven clusters. There were some differences
noted. In particular. ST-14 was located within ST-6 complex by UPGMA and
split decomposition, but BURST placed this ST within ST-I complex. ST-Il
and ST-13 are within the ST-IO complex by the methods ofUPGMA and split
decomposition but was not allocated to a BURST group. Similarly. ST-24 was
not included within ST-23 complex by BURST. ST-I complex, is very closely
related to ST-19 and its identity as a separate split is not entirely clear from the
trees drawn.
Table 6.5: Analysis of clustering of STs according to BURST (Singletons: ST-
II, ST-13, ST-22. ST-24. ST-26).
BURST ST-complex Central ST STs
group
1 I I 1,2,14
2 4 4 4,5,16
3 6 6,7
4 10 10 8,9,10,12.15
5 17 17 17,18,29
6 19 19 19,20,21,27,28,30
7 23 23,25
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Figure 6.2: UPGMA dendrogram generated from concatenated sequences
showing genetic relationships between 29 STs and naming of clonal complexes.
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Figure 6.3: Tree drawn by split decomposition analysis of 29 STs with clonal
complexes indicated by boxes.
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ST-6 .... 1ex
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6.4.iv Relationship between ST, capsular serotype and Restriction
Digest Patterns (RDP):
Capsular serotype was known for all 152 isolates (Table 6.3 and Table 6.4) and
there was complete correlation between capsular serotyping results between
three laboratories. Five isolates proved to be non-typeable. Serotype III was
most common (78 isolates, 44 of which belonged to ST-17), followed by,
serotype lA (I9 isolates), IB (17 isolates), V (IS isolates), II (8 isolates), VI (6
isolates) and VIII (4 isolates). Serotypes IV and VII were not represented in the
dataset. Capsular serotype was generally not restricted to specific STs and four
STs contained isolates with different capsular serotypes.
RDP typing results were known for 40 of the isolates within the dataset (Table
6.6). ROP type correlated closely with ST, isolates of the same RDP type were
identical by MLST or only differed at a single locus.
Table 6.6: Restriction Digest Pattern (ROP) compared with Sequence Type for
40 GBS isolates.
ST Allelic profile RDP Number
type of isolates
17 2,1, I ,2, I , I , I I11-3 30
29 2, 1,1,8, I, I , I 1I1-3 I
19 1,1,3,2,2,2,2 III-2 6
21 1,9,3,2,2,2,2 1II-2 I
23 5,4,6,3,2,1,3 III-I 1
25 5,4,6,3,8, 1,3 III-I I
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6.4.v Relationship between lineage, host and country of origin:
The dataset presented in this study was not specifically designed to investigate
the relationship between isolates and country or host of origin. However, the
following observations can be made (Table 6.3). ST -1 and ST-19 were
significantly associated with carriage (Yates corrected, p=O.004 and p=O.008,
respectively) and several different capsular serotypes were represented in these
STs. The 44 isolates within ST-17 were all serotype III. ST -17 was significantly
associated with invasive neonatal disease (Yates corrected, p=O.OOOOOO1). ST -23
contains serotype lA isolates (11/16, 68.6%) from carriage and invasive disease.
ST-1, ST -19, ST-17 and ST -23 each contain isolates isolated from Australasia,
Europe, Asia and North America, suggesting global dispersal.
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6.5 DISCUSSION:
A multilocus typing scheme for GBS based on seven housekeeping genes was
validated using a world-wide collection of capsular-typed isolates that included a
sub-group previously characterized by RDP.
The percentage of variable sites (1.2 to 2.5%) in the seven selected GBS genes
was comparable to that seen by Tettellin et al 145 in their analysis of sequence
variation in 19 genes from II GBS strains. The percentage of variable sites is
less than that seen in the related species, group A streptococcus'Y (5.1 to 7.6%)
and considerably less than Campylobacter jejuni 142 (9.2 to 21.7%), a Gram-
negative organism. The dnlds ratios for the seven GBS genes were all less than
one, which suggests that there is selection against amino acid change and is
consistent with most of the variation being selectively neutral. The genes chosen
were distributed around the chromosome and were located in the same
approximate location in both of the published GBS genome sequences, NEM316
144 and 2603 VIR 145. MLST results for the two published GBS genome
sequences showed that NEM316 was ST-23 and that 2603 VIR was a single
locus variant of ST -19.
A website for GBS MLST was set up and can be accessed at the following
address, http://sagalactiae.mlst.net.
The aim of this work was to establish an MLST typing system, however there
were sufficient numbers of isolates to make early observations about the
population structure of GBS. The most common STs in the dataset were ST -1,
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ST-17, ST-19 and ST-23. These four STs represented two-thirds of the isolate
collection. ST -19 and ST-I contain several di fferent capsular serotypes, and
were significantly associated with the carriage state. ST -17 is more
homogeneous and consists of serotype III isolates predominantly associated with
neonatal invasive disease. The STs were grouped together in similar fashion by
UPGMA, SplitsTrees and BURST.
The MLST findings are in accord with the results of Musser et al':', These
authors used MLEE to study the population structure of GBS. They found that 2
distantly related evolutionary lineages of GBS could be distinguished. The first
lineage contained a single electrophoretic type (ET -I) and consisted of serotype
III isolates, which had been isolated from neonatal disease. This presumably
corresponds to the ST-17 ofMLST. The second lineage ofMLEE was more
diverse and contained several subdivisions and numerous ETs, which may
correspond to the ST -19 complex or ST-I complex, which are more diverse,
with several STs and different capsular serotypes. Similar relationships between
GBS isolates have also been found using RDP typing 146 and PFGE II.
MLST shows that isolates with the same ST can have different capsular
serotypes. This could imply that the MLST scheme has insufficient
discriminatory power and groups isolates that are not closely related in genotype.
However, a similar variation in the serotype of isolates within a single genotype
was also shown by MLEE 13. The variation in serotype within a single ST, and
the presence of genetically diverse isolates with the same serotype, suggest that
the capsular biosynthetic genes ofGBS are subject to relatively frequent
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horizontal gene transfer, as is seen in Streptococcus pneumoniae 147. It has been
demonstrated that a single gene confers serotype specificity in GBS of capsular
types III and lA 148 and recombinational replacement of this gene with that from
an isolate of a different serotype would result in a change of capsular type.
However, thus far, horizontal transfer of capsular genes has not been shown for
GBS other than in the laboratory. An alternative, perhaps less likely explanation
is, that capsular serotyping may be prone to mistakes and is difficult to interpret.
In conclusion, the GBS MLST system appears to be sufficiently discriminatory
for epidemiological studies and provides a precise and unambiguous way of
characterising isolates ofGBS isolates. A website providing information about
allele sequences and sequence types has been set up. Results have confirmed
previous findings that a single clone of GBS (ST -17) seems to be frequently
represented in neonatal invasive disease.
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B: EVALUATION OF GBS MLST AS A TYPING SYSTEM.
6.6 AIMS:
To determine the efficiency ofGBS MLST as a typing method in comparison to
the current gold standard method, capsular serotyping.
6.7 INTRODUCTION:
In the evaluation of a new typing system, it is necessary to consider the
typability, reproducibility and discrimination of the new technique, and compare
these to the "gold standard" typing mechanism. In the case of GBS, the
developed MLST system is compared with capsular serotyping.
6.8 MATERIALS AND METHODS:
MLST was compared with capsular serotyping using a collection of299 GBS
isolates collected from the Oxford area as a result of enhanced surveillance for
invasive neonatal infection and a carriage study of asymptomatic carriage of
GBS in pregnant women, as previously described (Chapters 3,4). Methodology
for MLST and for capsular serotyping is described in Materials and Methods
(Chapter 2).
Typability (%) was calculated from the number of isolates that could be
allocated to a sequence type for MLST and for capsular serotyping.
Reproducibilty (%) was assessed from the proportion ofMLST (n=60) reactions,
which were repeated at random and yielded the same result. Reactions were
repeated from the PCR stage onwards. Measures of discrimination (D) and 95%
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Cl were calculated according to equations described above (Chapter I,
Introduction ).
6.9 RESULTS:
MLST and capsular serotyping by latex agglutination were carried out on 299
isolates. The results are shown in Tables 6.7.
Table 6.7: Sequence types defined by MLST and Capsular Serotypes, according
to frequency of identification in 299 strains ofGBS.
ST Number Capsular Serotype Number
17 52 III 113
1 50 lA 61
23 50 V 55
19 40 ID 35
8 17 II 22
12 11 VI 4
28 7 VII 2
2 6 IV 1
10 6 VIII 1
22 5 Non- Typeable 5
24 5
6 4
7 3
4 2
26 2
107 2
109 2
115 2
130 2
Other 31
Total 268 Total 299
Footnote to Table 6.7: Other STs identified only once in collection: ST-9, 18,20,
27,65,78,88,103,104,106,108,110,111,112,113,114, 116, 117, 118, 128,
129,131,132,133,134, 136, 13~ 13~ 139, 140, 141.
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6.9.i Typability:
A1I299 (100%) were successfully typed by MLST. Five of299 (1.7%) isolates
were non-typeable by capsular serotyping.
6.9.;; Reproducibility:
Sixty of2093 (2.9%) MLST reactions were repeated, with all reactions
identifying the same allele when repeated, giving a repeatability of 100%.
Reproducibility was not carried out for latex agglutination results. A subset of
isolates (n=39) had capsular serotyping carried out in a second laboratory, using
capillary agglutination rather than latex agglutination. The results of capsular
serotyping were concordant between the two methods for all 39 isolates.
6.9.;;i Discrimination:
Simpson's index of diversity (D) and 95% Cl were calculated for the capsular
serotyping by latex and for MLST on the dataset. The results are shown in Table
6.8. It can be seen that 0 was higher for MLST compared to capsular serotyping.
The 95% Cl do not overlap, suggesting that this difference is significant.
Table 6.8: Index of Diversity (D) and 95% Cl for MLST and capsular serotyping
for 299 isolates ofOBS.
D 95%CI
Capsular
seroty~in! 0.77 0.74-0.79
MLST 0.89 0.88 - 0.91
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6.10 DISCUSSION:
MLST has been carried out on 299 GBS isolates and compared with the gold
standard method of typing GBS, capsular serotyping.
MLST performs well on all three factors assessed, typability, reproducibility and
discrimination. In particular, all isolates could be allocated an ST, whereas 1.7%
were non-typeable by capsular serotyping. On repetition of a proportion of
MLST reactions, there was high reproducibility with no misidentification of
alleles or STs. Additionally, MLST proved to be more discriminating than
capsular serotyping (D value, 0.89 compared to 0.77).
In conclusion, MLST is a discriminatory and reproducible typing method for
GBS.
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Chapter 7: The Population Biology of GBS in carried
and invasive isolates from Oxford, UK
7.1 AIMS:
To study the population biology of carried and invasive neonatal GBS from the
Oxford area. To estimate the invasive potential ofGBS STs in the causation of
neonatal disease.
7.2 INTRODUCTION:
A collection of carried GBS from pregnant women were collected over a 2-year
period from women attending antenatal care in the Oxford area. A collection of
GBS, representing cases of both early and late onset neonatal disease from the
Oxford area were assembled both retrospectively from stored isolates and
prospectively from enhanced surveillance. These two collections of GBS isolates
were put together to represent the ecology ofGBS in neonatal infection and
formed the basis of a more detailed investigation of the population structure of
GBS in this setting.
7.3 MATERIALS AND METHODS:
Methods for assembly of isolate collections have been described in Chapters 3
and 4. Methods for MLST and computational analyses have been described in
Chapter 2. Specifically, concatenated sequences representing the sequence types
seen were entered into the MEGA and SplitsTrees programmes. Tests of
nucleotide diversity (n) and pairwise differences (Il) were calculated using
MEGA. Simpson's Index of diversity (0) was calculated for the carried and
invasive population. Ninety-five percent Cl around the index were calculated
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according to described methods (Chapter 2). Invasiveness of STs was estimated
by calculation of odds ratios from 2x2 tables.
7.4 RESULTS:
7.4.; Characteristicsof the study population:
The study population of GBS consisted of 299 isolates, of which 109 were from
invasive neonatal disease and 190 were from asymptomatic carriage in pregnant
women. All isolates were collected from the Oxford area. MLST was performed
on the entire collection and showed that there were 51 STs identified, of which,
carried isolates consisted of38 STs (Table 7.1) and invasive isolates, 29 STs
(Table 7.2). The most prevalent STs in the carried population were, ST-23, ST-
19 and ST-I accounting for some 51.6%. In contrast invasive isolates were
allocated to ST-17 in 30.3% of cases, with ST-l (15.6%), ST-23 (11.9%) and
ST-19 (11.0%) occurring less frequently.
7.4.;; Capsular serotyping:
Examination of capsular serotype revealed that, in the case of the more common
STs, only ST-17 was homogeneous, with all 52 isolates of ST-17 being capsular
serotype III. ST-23 was predominantly associated with capsular serotype lA
(47/50 isolates, 94.0%), ST-I with serotype V (39/50, 78.0%), ST-8 with
serotype IB (15/17,88%) and ST-19 with serotype III (37/40, 92.5%).
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Table 7.1: Carried GBS isolates from Oxford with ST, allelic profile and
capsular serotype (in order of frequency of identification).
ST Number(%) Capsular Serotype(Number)
23 37 (19.5) lA (35), V (2)
1 33 (17.4) V(25), VI(2). VII(2), VIII( 1), IV(l). 11(1).NT( 1)
19 28 (14.7) III (25), II (3)
17 19(10.0) III (19)
8 12 (6.3) IB (12)
12 10 (5.3) IB (6), II (2), V (1), NT (1)
10 5 (2.6) II (3). IB (2)
22 5 (2.6) V (4), II (1)
28 5 (2.6) " (3), III (1), NT (1)
24 4 (2.1) lA (4)
2 3 (1.6) V(1), VI (I), II (I)
6 3 ( 1.6) IB (2), VI (I)
4 ItO.5) lA
7 1(0.5) lA
26 I (0.5) V
65 I (0.5) IB
78 I (0.5) II
88 I (0.5) lA
103 1(0.5) lA
104 I (0.5) IB
107 1 (0.5) III
110 1 (0.5) V
111 I (0.5) III
112 I (0.5) III
113 I (0.5) IB
114 I (0.5) lA
115 I (0.5) III
116 I (0.5) IB
117 I (0.5) V
118 ItO.5) IB
128 !_i0.5) III
129 I (0.5) III
130 1 (0.5) V
131 I (0.5) III
132 1 (0.5) lA
139 I (0.5) V
140 I (0.5) II
141 I (0.5) V
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Table 7.2: Invasive GBS isolates from Oxford with ST, allelic profile and
capsular serotype (in order of frequency of identification).
ST Number Capsular Serotype(%) ~umber)
17 33 (30.3) III (33)
1 17(15.6) V(l4), III (2), IB (I)
23 13(11.9) lA (12),111 (I)
19 12(11.0) III (12)
8 5 (4.6) IBJ.3), IA(I ), III (I)
2 3 (2.8) NT (2), IIJ I)
7 2 (1.8) IAil), V (I)
28 2 (1.8) II (2)
109 2 (1.8) III (2)
4 I (0.9) lA
6 1 (0.9) ]B
9 1(0.9) IB
10 1(0.9) IB
12 1 (0.9) IB
18 1 (0.9) III
20 I (0.9) III
24 1(0.9) lA
26 1 (0.9) V
27 I (0.9) III
106 1 (0.9) III
107 1 (0.9) III
108 1 (0.9) 111
115 1 (0.9) III
130 1 (0.9) II
133 1 (0.9) III
134 1 (0.9) II
136 1 (0.9) II
137 1 (0.9) III
138 1(0.9) III
7.4.ii; Representation of population byphylogenetic tree:
7.4.W.a Distance versus discrete tree-building methods. Two
methods of tree building were used to analyse the data. Firstly the maximum
parsimony method was used, this method utilises the data of individual
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nucleotide sites. Figure 7.1 shows the maximum parsimony tree for the data. The
data are grouped into the same groups or complexes defined by BURST
(Chapter 6), which have been called ST-I complex, ST-6 complex, ST-IO
complex, ST-17 complex, ST-19 complex and ST-23 complex. The statistical
support for the resultant tree was tested and bootstrap values have been added to
the branches. The bootstrap values associated with the branches of the maximum
parsimony tree are all less than 70%, which suggests that the tree does not
reliably represent the relationships contained within the dataset.
The neighbour joining tree, which is generated using a different algorithm to
maximum parsimony and is based upon measurement of evolutionary distance
between pairs of sequences, was generated. Although the exact relationship of
the STs within each complex is different, the same clustering ofSTs into
complexes is seen. The ordering of the complexes is different however (Figure
7.2).
7A.m.b Tree-building with removal of long-branches. Given the
finding that there is conflict within the tree suggested by low bootstrap values,
the long branches of more distantly related strains, shown in the trees (ST-4,
26,103,141) have been removed from the dataset and a UPGMA tree resulting
from this dataset is shown in Figure 7.3. This analysis shows that the complexes
around ST-1, ST-6, ST-17, ST-19 and ST-23 are associated with bootstrap
values of greater than 70%.
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Figure 7.2: Comparison of maximum parsimony tree (left) and neighbour joining
tree (right) for concatenated sequences of 51 STs of carried and invasive GBS.
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Figure 7.3: UPGMA tree for concatenated sequences of 47 STs of invasive and
carried GBS. Long branches ST-4, 26, 103, 141 have been pruned.
Bootstrap values are indicated. Colour scheme, as for Figure 7.2.
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7.4.iii.c Split decomposition analysis. Split decomposition has
been used to attempt to resolve relationships between the 7 clusters shown by the
maximum parsimony and neighbour joining tree. The tree produced from the
entire dataset is shown in Figure 7.4 shows a bipolar distribution of STs with
ST-17 complex, ST-19 complex, ST-23 and ST-I complex at one pole and ST-
10 complex at the other pole. At nodes where multiple STs were located
together, trees were formed with only those STs represented to indicate the
relationships at those nodes.
The long branches ST -4, 26,103,141 were removed from the dataset and a
further tree formed. This analysis (Figure 7.5) shows the population best
represented by a network. ST-I complex and ST-19 complex cluster together as
do ST -23 complex and ST -17 complex. It can also be seen that ST -130 is
distorting the network and as it is only represented by two isolates in the
collection it is likely to be a new recombinant. This branch has been removed
and the data reanalysed. Figure 7.6 shows the resultant tree. This time, the same
clusters are revealed, but the relationships between the clusters are complicated
and better represented by a network connecting the six clusters, rather than a
branching pattern.
102
Figure 7.4: Tree formed by split decomposition of 51 STs of invasive and carried
GBS. The boxes show the relationships of STs clustered together at the central
nodes of the tree.
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Figure 7.5: Tree formed by split decomposition for 47 STs of invasive and
carried GBS. Long branches ST-4, 26, 103, 141 have been pruned. The position
of ST -130 is indicated by a box.
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Figure 7.6: Tree formed by split decomposition for 46 STs of invasive and
carried GBS. Long branches ST-4, 26, 103, 141 and 130 have been pruned. The
boxes show the relationships ofSTs that are clustered together at nodes of the
tree. Colour scheme as indicated in Figure 7.2.
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7.4.iv Diversity in the studiedpopulations:
Diversity was examined using concatenated sequences of the 51 STs which
represent the collection of299 isolates. Thirty-eight STs of the carried
population were compared with 28 STs of invasive isolates. It can be seen that
the diversity was approximately the same in the two populations in that there are
an average of 5 nucleotide changes per 1000 base pairs of DNA (1t= 0.005) in
both carried and invasive populations ofGBS. The segregating site (S) count and
the number of pairwise differences (IT) are also similar (Table 7.3). Simpson's
Index of diversity and 95% Cl for the carried population was 0.89 (87.4 - 91.5)
and was lower for the invasive population at 0.86 (81.7 - 90.3). It can be seen
that the 95% Cl for the two populations are overlapping which suggests that
although there is a tendency for the carried population to be more diverse, this
finding is not significant in this dataset.
Table 7.3: Comparison of Carried and Invasive GBS using tests of nucleotide
diversity.
Test of Genetic Diversity Carried Invasive
Number of Sequences (n) 38 29
Length of Se_quences (L) 3456 3456
Number of Segregating sites (S) 72 67
Segregating sites per site (SIL) 0.02 0.02
Nucleotide diversity (1t=TIlL) 0.005 0.005
Average number of pairwise nucleotide differences _CII) 18.5 17.9
Simpson's index of diversity (D) 0.89 0.86
A verage pairwise nucleotide differences between STs (IT) were calculated for
the major clonal complexes seen in the dataset. Pairwise differences (IT) ranged
from 1.0 to 6.0 within the clonal complexes (Table 7.4).
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Table 7.4: Average number of pairwise differences (II) within clonal complexes
± Standard error of the mean (S.E.M).
Clonal complex II (± S.E.M)
ST-l complex 3.7 (± 1.2)
ST-6 complex 1.0 (± 1.2)
ST-lO complex 2.2 (± 0.7)
ST-17 complex 3.7 (± 0.8)
ST-19 complex 2.6 (± 0.8)
ST-23 complex 6.0 (± 1.8)
Average pairwise nucleotide differences between the major clonal complexes
were then calculated (Table 7.5). It can be seen that the number of pairwise
differences was higher for STs located in different clonal complexes than for
those located in the same clonal complexes. In other words, diversity within the
clonal complex is lower than that seen between any two of the clonal complexes.
It can also be seen that differences in the values of pairwise differences are not
as marked between two areas of the tree where clonal complexes cluster more
closely, in particular between ST-l9 complex and ST-l complex and also with
ST-IO complex and ST-6 complex
Table 7.5: Average number of pairwise differences (II) between clonal
complexes, ± Standard error of the mean (S.E.M).
II
Clonal ST-lc ST-6c ST-IOc ST-17c ST-19c
complex
ST-6c 13.2± 2.8
ST-IOc 20.9± 3.5 8.5±2.6
ST-17c J9.9±3.7 26.1 ±4.5 23.8±4.3
ST-19c 10J ±2.5 12.8±3J 19.9±3.9 25.6±4.4
ST-23c 31.6±5.S 30.9±S.O 27.8±4.8 20.1±4.4 25.4±4.6
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7.4.v Association of STs and clonal complexes with invasiveness in
neonates: ST-17 proved to be the only ST that was significantly associated
with invasive disease in neonates (p = 0.00002, Table 7.6». This finding was
particularly true of late-onset neonatal infection, where ST-17 was associated
with an odds ratio of 6.0 (Table 7.7). No ST was significantly associated with
carriage. Following the grouping ofSTs into clonal complexes, it can be seen
that again, ST -] 7 clonal complex was strongly associated with neonatal invasive
disease (Table 7.8) and ST-23 complex was significantly associated with
carriage in this analysis. ST-] complex, ST-I 0 complex and ST-19 complex
showed no association with either carriage or invasive disease. ST-] 9 complex,
can be seen to be different to ST-17 complex since despite having a majority of
serotype III isolates, it is not significantly associated with invasive disease.
Capsular serotype III was significantly associated with invasive disease (OR 3.4
(2.0-5.7), p-value 0.000002).
Table 7.6: Calculation of invasiveness ofSTs, as measured by odds ratios (OR)
with 95% Cl and level of significance.
ST No. No. OR 95%CI P-value
invasive(%) carried (%)
23 13 (11.9) 37 (19.5) 0.6 0.3-1.2 0.1
1 ]7(15.6) 33 (17.42 0.9 0.4-1.7 0.8
19 ]2 (11.0) 28 (14.7) 0.6 0.3-1.6 0.5
17 33 (30.3) ]9 (10.0) 3.9 2.0-7.7 0.00002
8 5 (4.6) ]2 (6.3) 0.7 0.2-2.3 0.7
12 1 (0.9) 10(5.3) 0.2 0-1.3 0.06 *
Yates corrected test of significance used, except * Fisher exact test used.
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Table 7.7: Calculation of invasiveness. as measured by odds ratios. of clonal
complexes of OBS for early and late onset neonatal invasive disease. Ninety five
percent Cl and level of significance are listed.
ST Early onset neonatal sepsis Late onset neonatal sepsis
No.(%) OR Cl P-value No.(%) OR Cl P-value
23 10 (15.6) 0.8 0.3-1.7 0.6 3 (6.7) 0.3 0.1-1.1 0.07
1 13(20.3) 1.2 0.6-2.6 0.7 4 (8.9) 0.5 0.1-1.5 0.2
19 7 (10.9) 0.7 0.3-1.8 0.6 5(11.1) 0.7 0.2-2.1 0.7
17 15 (23.5) 2.8 1.2-6.2 0.01 18 (40.0) 6.0 2.6-13.8 0.000002
8 4 (6.3) 1.0 0.3-3.5 0.6* 1 (2.2) 0.3 0.1-2.6 0.5*
Total 64 45
Yates corrected test of significance used, except * where Fisher exact test used.
Table 7.8: Calculation of invasiveness, as measured by odds ratios, of clonal
complexes of OBS neonatal invasive disease. Ninety five percent Cl and level of
significance are listed.
Clonal No. Invasive No. Carried OR 95%CI p- value
Complexes (%) (%)
ST-17 complex 40 (36.7) 28 (14.7) 3.4 1.9-6.1 0.00003
ST-23 complex 14 (12.8) 44123.21 0.5 0.2-1.0 0.004
ST-10 complex 13 (11.9) 38_{_20.0) 0.5 0.2-1.1 0.1
ST-1 complex 21(19.3) 38 (20.0) 1.0 0.5-1.8 1.0
ST-19 complex 19(17.4) 38 (20.0) 0.8 0.4-1.6 0.7
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7.5 DISCUSSION:
The population ofOBS studied represents a collection of almost 300 isolates
assembled from a defined geographical area of the UK over a similar time
period. The purpose of the study was to use this collection, which represents the
ecology ofOBS in the setting of neonatal invasive disease, to examine the
population biology ofOBS.
Analysis of population structure has shown that there are 6 major clusters of
OBS, all of which contain isolates from carriage and invasive disease. Three
different methods were used to demonstrate this pattern of clustering, UPOMA,
split decomposition and calculation of pairwise differences (IT). The major
complexes seen were ST -1 complex, ST -10 complex, ST -17 complex, ST-19
complex, ST-23 complex and ST-6 complex.
In order to define relationships between the complexes, long branches were
removed and subsets of strains analysed. Using the tree building methods of
neighbour-joining and maximum parsimony some of the major branches of the
trees were associated with low bootstrap values. This finding suggests that there
is contlict within the tree, that is, the branching pattern of the tree has been
distorted by the presence of recomb inationa Ievents. By eliminating long
branches of more distantly related strains and reconstructing the UPOMA tree,
the bootstrap values associated with the major complexes were all above 70%
supporting their identity as clonal complexes.
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A further possibility is that the branching tree structure is not able to fully
describe the relationships between the major complexes. The split decomposition
method was used as an alternative way to demonstrate relationships between
clusters. The resultant network revealed a similar pattern with the same 6 major
complexes, but a network rather than branching lines interconnecting these
complexes. This is consistent with the presence of recombinational events
occurring in the population ofGBS that are interfering with a tree like branching
structure of the population.
Measures of diversity, were calculated to determine whether the clonal
complexes described by the trees can be supported numerically. The amount of
measured diversity within and between complexes supports the identification of
ST-23 and ST-17 as clonal complexes. The situation was more ambiguous with
ST -6/ ST-10 complexes and ST-19/ ST -I complexes, in that. although the
diversity was greater between than within the complexes, the difference was not
as great as for ST-17 and ST-23 complexes.
Epidemiological data were then combined with the phylogenetic results. ST-17
is significantly associated with neonatal invasive disease and was represented in
the invasive collection three-fold more frequently than other STs. This finding
was unique, in that no other ST was significantly associated with either invasive
disease or carriage. In particular, ST -19, which shares the same capsular
serotype (III) as ST-17, was not associated with invasive neonatal disease. These
findings were confirmed when the data were reanalysed using complexes rather
than individual STs. The association of ST -17 complex with invasive disease
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was maintained and ST-23 complex proved to be significantly associated with
carriage.
Capsular serotyping revealed that ST-17 complex isolates were serotype III.
None ofthe other major STs were uniquely associated with a single capsular
serotype, ST -1 tended to be V and similarly, ST -8 was associated with IB, ST-19
with III and ST-23 with lA. That a sequence type can have more than one
serotype suggests that there may be recombination occurring across the capsular
locus. This has not been shown to occur in vivo, however.
Serotype III is numerically most prevalent in both carried and invasive isolates
and was significantly associated with invasive disease. Whether this association
is due to the presence of ST -17 complex isolates within type III isolates seems
likely although the numbers are too small to adequately investigate heterogeneity
of ST invasiveness within the same capsular type. It can be seen that ST-17
complex type III isolates are associated with invasive disease whereas ST -19
complex type III isolates are not. This suggests that the invasiveness of ST -17
complex isolates may be independent of capsular type III and that another factor
may be responsible for virulence of this clonal complex in neonates.
Several interesting observations can be made from these analyses of the
population structure ofGBS. There are a number of successful clonal complexes
ofGBS responsible for human carriage and invasive disease. One complex (ST-
17 complex) is hypervirulent in neonates. The remaining complexes are
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successful well-adapted complexes, as indicated by their prevalence in the
population of both carriage and invasive isolates.
Recombinational events occur in GBS allowing isolates with identical allelic
profiles to have different capsules and resulting in distortion of the tree like
structure ofGBS.
The association of invasive disease with ST -17 complex was particularly strong
for late onset neonatal disease. This is an important finding, especially since the
introduction of intrapartum prophylaxis to women has proved to have no effect
on prevalence of late onset neonatal disease. Further study of this hypervirulent
clone ofGBS may contribute to the understanding of the pathogenesis of
neonatal GBS disease.
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Chapter 8: Invasive GBS disease in human cases of age
greater than 60 years.
8.1 AIMS:
To investigate GBS invasive infection in adults over 60 years, as this age group
is at increased risk. Clinical presentation was recorded and isolates were
characterised by MLST to determine the population ofGBS responsible for
disease in this setting and to see whether hypervirulent clones of GBS could be
defined.
8.2 INTRODUCTION:
The rate of invasive GBS disease has generally increased over the last few
decades 92.More than two-thirds ofGBS disease in the USA occurs in adults'".
GBS infections commonly affect those with underlying medical conditions,
including diabetes mellitus, liver cirrhosis, malignancy, vascular disease and
decubitus ulcers" . Studies have suggested that 70-93% of adult cases ofGBS
infection had one or more underlying medical illness62.93.94.Indeed, the
increasing rate ofGBS disease may be attributed, in part, to an expanding
population of adults who are living longer with significant medical co-
morbidities.
Clinical manifestations ofGBS in adults are numerous and varied. Common
diagnoses include skin and soft tissue infection, bone and joint (native and
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prosthetic) infection and pneumonia. Less frequently, endocarditis, meningitis
and endophthalmitis are the presenting syndromes" .
Serotype distribution of GBS isolates indicates that type lA, III and V are
common in the adult population 149 and is an important factor to consider in the
planning of a GBS vaccine strategy aimed at elderly patients.
The mean age of non-pregnant adults with invasive GBS disease is 60 years and
elderly adults in nursing home accommodation appear to be at particular risk 95.
Annual incidence rates of GBS disease in adults have been estimated in the USA
as 4.1 to 7.2/}00,000 population 95. Figures from the 'UK have not been reported
in recent times.
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8.3 MATERIALS AND METHODS:
8.3.; Isolate collection:
GBS isolates were collected in the Oxford area from participating hospitals as
described in Chapter 3. Only GBS isolates from cases aged 60 years or over
were included for study (n=70).
Age at onset of infection was recorded for each case and where the case records
were available for examination (JRH) clinical diagnosis was listed.
8.3.;; MLST methods:
MLST was carried out on the collection as described in Chapter 2.
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8.4 RESULTS:
Seventy cases of invasive GBS disease in patients> 60 years were identified
from the enhanced surveillance study. The age distribution of cases is depicted
in Figure 8.1 and 8.2. Case records were retrieved from 26 patients, who had
been admitted the Oxford Radcliffe Hospitals. Admitting diagnosis was recorded
for these cases and is indicated in Table 8.1. The majority of cases (16/26,
61.5%) presented with skin, soft tissue or bone and joint (native or prosthetic)
infection.
Figure 8.1: Number of cases of invasive GBS disease according to age group.
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Figure 8.2: Numbers of invasive GBS cases from adults in Oxfordshire in age
groups, 60 to >90 years. Total number of cases (columns, with error bars) and
age- adjusted rates (lines) are indicated.
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Table 8.1: Clinical diagnosis of cases of invasive GBS at age> 60 years.
Clinical dlaznosis Number
Skin and soft tissue 6
Native bone or joint infection 6
Prosthetic joint infection 4
Bacteraemia, no focus 5
Pneumonia 1
Infective endocarditis 2
Urinary tract sepsis 1
Abdominal infection I
Twenty-seven STs were identified in the collection. Clustering of STs, based
upon concatenated sequences, is shown in Figure 8.3, by the algorithm of
UPGMA and Figure 8.4, using split decomposition.
The clonal complexes identified previously (Chapter 7) were again seen. Six
major complexes were present on both trees (UPGMA and SplitsTree). The most
frequently identified complex was ST -1 complex, which accounted for 17
isolates (24.3%). ST-19 complex, ST-IO complex and ST-23 complex were also
commonly seen. Fewer isolates fell into ST-17 complex (n=6) and ST-6 complex
(n=3). When the population of isolates from invasive GBS disease in cases >60
years was compared with that of asymptomatically carried GBS from pregnant
women, it can be seen that no clonal complex was significantly associated with
disease in cases> 60 years (Table 8.2) and the odds ratios were all close to 1.0.
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Table 8.2: Numbers (%) ofSTs isolated from invasive disease in age >60 years
compared with asymptomatically carried isolates, with p-values,
Clonal Invasive >60 yrs Carried isolates Odds ratios P-value*
Complex Number (%) Number (%) (95% Cl)
ST -23 complex 11 (15.7) 44 (23.2) 0.6 (0.3-1.3) 0.3
ST-IO complex 15(21.4) 38 (20.0) 1.1 (0.5-2.2) 0.9
ST -I complex 17 (24.3) 38 (20.0) 1.3 (0.7-2.6) 0.6
ST-19 complex 14 (20.0) 38 (20.0) 1.0 (0.5-2.1) 0.9
* Yates-corrected test of significance
Abbreviations: Cl. 95% confidence intervals.
119
Figure 8.3: UPGMA tree with bootstrap values for concatenates sequences of
STs identified in collection of isolates of invasive GBS from adults >60 years
(Numbers in brackets indicate the number of isolates identified as that ST,
except where blank where n=l ).
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Figure 8.4: SplitsTree diagram for STs identified in collection of isolates of
invasive GBS from adults >60 years.
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8.5 DISCUSSION:
This study is an investigation of invasive GBS infection in older adults (>60
years) in the Oxford area. A sample of70 isolates were studied. Invasive GBS
disease is commonly seen in this group. with clinical presentation frequently
involving skin. soft tissue or osteoarticular infection.
MLST was carried out on the isolates and showed that there are four important
clonal complexes accounting for more than 80% of the invasive GBS disease
seen in the adults> 60 years. These are ST-I complex, ST-IO complex, ST-19
complex and ST-23 complex. The clustering seen using the methods ofUPGMA
and split decomposition is similar to that seen in neonatal invasive GBS and
carried GBS (Chapter 7).
It can be seen, from comparison with a collection of isolates isolated from
asymptomatic carriage in the same geographical area that there is no significant
difference between the two groups. Clonal complexes that are prevalent in
asymptomatic carriage are also successful as pathogens in the setting of invasive
GBS disease in the adults> 60 years. This is in contrast to the case of neonatal
GBS infection, where ST-17 complex is hypervirulent. ST-17 is uncommon as a
pathogen in the adults> 60 years.
The collection of carried isolates from pregnant women may not be the most
representative of carriage in the adult population over 60 years of age. Future
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studies utilising collections of carried isolates from this age group may be more
appropriate.
It can be concluded, from this investigation, that successful lineages ofOBS
identified in carriage in pregnant women are also the most prevalent lineages
associated with invasive OBS disease in older adults and that hypervirulent
clones have not been identified.
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Chapter 9: Relationship between bovine and human
group B streptococcus.
This chapter has been published as:
Bisharat, N., Crook, D.W.M., Leigh. J., Harding, R.M., Ward, P.N., Coffey, T.J.,
Maiden, M.C .. Peto, T., Jones. N. Hyperinvasive Neonatal Group B
Streptococcus Has Arisen From A Bovine Ancestor. Journal of Clinical
Microbiology 2004: 42(5): 2161-2167 (Appendix 3).
9.1 AIMS:
To investigate the relationships of human and bovine GBS isolates using MLST
data. In addition, to determine whether human and bovine GBS are distinct
populations. or whether there is some overlap between the two populations given
the link suggested by epidemiology between the two populations. Lastly, to
examine possible evolutionary scenarios for the recent emergence of human-
pathogenic GBS and their relationship to bovine GBS.
9.2 INTRODUCTION:
GBS was initially described as an animal pathogen causing bovine mastitis in
188715°.Human infections caused by this bacterium were only reported 50 years
later in the 1930s1.151.Neonatal disease was rarely reported until1960s when
numerous reports linked neonatal infections with this organism2,3,152, and by the
1970s GBS had become the leading neonatal pathogen54.105,153.The reasons
behind the rapid and sustained emergence of GBS neonatal disease have not
been completely elucidated. A possible explanation has been association with
bovine GBS98,154, but most studies have concluded that the human and the
bovine populations are distinct and unrelatedl55,156.
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9.3 MATERIALS ANDMETHODS
9.3.i Bacterial isolatecollections.
The bovine isolates (n= 111) were obtained from milk samples of cows with
evidence of clinical mastitis. Twenty-five isolates were provided by the Institute
of Animal Health (IAH), Compton, Berkshire, UK. Twelve of these had been
collected by the Central Veterinary Agency at Weybridge, Surrey, UK, during
the mid 1950s. The remaining isolates (n= 13) were collected and supplied during
1991-1992 by the Milk Marketing Board to the IAH. A further 86 isolates were
purchased from the Veterinary Laboratories Agency (VLA), Bury St Edmunds,
Suffolk, UK. These had been collected between 1987-1996 from farms around
the UK and represented a collection of diverse geographical origin. Each isolate
was a single isolation from an individual cow within a herd and additional
isolates were not collected from the same herd. For interest, four disease-causing
isolates collected from other animals (elephant, dog (n=2), and goat) were
included, which were supplied by the VLA.
The human isolates comprised 152 invasive and carriage isolates from the UK,
USA, Japan, New Zealand, Thailand, Singapore, and Israel, which were
characterized in a previous study and represent the global collection described in
Chapter 6.
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9.3.;; Identification and characterizationof isolates.
Methods described previously for the isolation of isolates. DNA extraction and
MLST. were followed. Capsular serotyping was carried out using the latex
agglutination method.
9.4 RESULTS:
9.4.i Genotypesidentified.
Fifty STs were represented in the whole collection, of which 26 were identified
in humans only, 17 were unique to the bovine isolates and 3 were present in
isolates from both humans and bovines. The remaining 4 STs were associated
with isolates from other animals. two from dogs and one each from an elephant
and a goat. The most common STs were ST-67 accounting for 73 of the III
(65.8%) bovine isolates and ST -17 that was found in 44 of the 152 (29.0%)
human isolates. A total of 31 STs were identified only once in this isolate
collection. The characteristics of the genotypes identified in the dataset are
shown in Table 9.1.
9.4.ii Capsularserotyping.
Seventy six percent of the bovine isolates were non-typeable (Table 9.1). For the
typeable isolates. serotype II was the most common (n=22), the remaining four
isolates were characterized as serotype III (n=3) and serotype lb (n=l ). In
contrast, only 3.3% of the human isolates were non-typeable. The majority of
human isolates belonged to serotype III (51%). Eight isolates (5.3%) from the
human collection belonged to serotype II.
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Table 9.1: Characteristics of Main GBS Sequence Types according to Serotype,
Host. and Disease State.
ST Allelic No.of Serotype Host Disease state
profile* isolates (No. of (No.of (No. of isolates)
in ST isolates}_ isolates)
67 13.1.1.13.1.1.5 73 II (14). IB (I). NT B(73) BM(73)(58)
17 2.1.1.2.1.1.1 44 111(44) H(44) NI(33). AC(9). AI(2)
I 1.1.2.1.1.2.2 21
V(9). VIII(4). VI(4). H(21) AC (16). AI (3). NI (2)II1(2). IS( I). NT( 1)
19 1.1.3.2.2.2.2 21
III( 17).11(2). V( I). H(20). B(I) AC(14). NI(3). AI(2).NT(I) NC(I). BM (I)
23 5.4.6.3.2.1.3 17
IA(II ).111(4). V(I). H(l6).B(1) AC(7). NI(5). AI(3).NT(I) NC(I). BM (I)
61 13.1.1.13.1.1.1 <I III (I). II (2). NT (6) B(9) BM(9)
2 1.1.3.1.1.2.2 8 II (7). NT (6) B(6). H(2) BM (6). AI (2)
8 4.1.4.1.3.3.2 7 IB(6).NT(I) H (7) AC(4). NI(I), AI(2)
10 9.1.4.1.3.3.2 5 1S(3). 11(1).NT(I) H(5) AC(2), NI( I). AI(2)
11 9.3.7.1,3.3.2 5 111(5) H(5) AI(5)
76 13.1.1.13.1.14.1 5 II (I). NT (4) B(5) BM(5)
7 10.1.2.1.3.2.2 3 lA (3) H (3) AC (I). NI (2)
12 10.1.4.1.3.3.2 3 IB (3) H (3) NI(2). AC(I)
26 1.1.5.4.1.4.6 3 V(3) H (3) AC(2). NI(I)
28 1.1.3.5.2.2.2 3 11(3) H(3 ) AC(2). NI(I)
72 13.1.1.13.1.2.5 3 NT (3) B (3) BM (3)
4 l.1.4 .1.1.3.4 2 lA (2) H(2l AC (I). NI (I)
15 9. 1.4.I.5.3.2 2 18(2) H (2) AI(I ). N1(1)
22 13.3.1.3.l.1.1 2 11(2) H(2l AC(I). AI( I)
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Table 9.1 continued
No.of Serotype Host Disease stateST Allelic profile" Isolates/
ST (No. of isolates) (No.of isolates) (No. of isolates)
5 12,1.4,1,1,3.4 I lA (I) H (I) AC(I)
6 9,1,2,1,3,2.2 I IB (I) H (I) AC (I)
9 8,1.4.1,3.3.2 I IB (I) H (I) AC(I)
13 11,3,4,1,3.3.2 I VI( I) H(I) AC(l)
14 1,1.2, I ,5,2.2 I VI(I) H(I) AC(I)
16 I, 1,4,1,6.3.4 I IA(I) H (I) AI( I)
18 3,1,1.2. I.1.1 I III( I) H (I) NI(I)
20 1,2,3,2,2.2,2 1 Ill( 1) H(l) NI( I)
21 1,9,3,2,2,2,2 1 I1I(1) H (I) NI( 1)
24 5,4,4,3.2,3.3 1 IA(I) H (I) AC(I)
25 5,4,6,3,8,1,3 1 III( 1) H (1 ) NI(l)
27 1,1,3,4,2,2,2 1 III( 1) H(I) AI( I)
29 2,1,1.8,1.1, I I III( 1) H(l) NI( 1)
30 1,1.8,2.2.2.2 1 V(1) HO) AC(I)
62 13,1,1,13,11,1,5 I II (I) B(I) BI (I)
63 13,1,1.2,1,10,1 1 NT(I) B (I) BI (I)
64 13,1,1,2.1,1.1 1 III (I) B(1) BI (1)
69 13,1,1.16,1.1,5 I NT(!) B (I) BI(l)
73 13,1,1,13,14,9,5 I NT(I) B(I) BI(l)
74 13,1,1,13, 1,13,5 I NT(I) B(1) BI(1)
75 13,1,14,13.1,1,5 1 NT (I) B (I) BI(I)
79 13,1,1,13,14,1,5 1 NT(I) B (I) BI(I)
80 19,1,1,13,1,1,5 1 II (1 ) B (I) BI(l)
81 1,12,3,2,2,1,2 1 NT(I) D(1) DJ (I)
82 20,13,15,1,15.1 ,5 I NT(I) E (1) El (I)
83 2,1,1,2,14,1,1 I III (I) B (I) BI (1)
84 10,1,2,1,3,1.2 1 NT(I) D (I) DJ (1)
85 13,1,17,15,1,1.5 I NT(I) B (I) BI (I)
86 1,1,3,2.2,1.2 1 NT(I) G(1) GI (I)
100 13,1,1,13,1.17.5 I NT(I) B(I) BI (I)
101 13.1, I. 13.1.18,5 I II ( I ) B (I) BI (I)
Abbreviations: ST. sequence type; NT, non-typeable; A, human adult; B, bovine;
M, mastitis; H. human; N, human neonatal; I, invasive disease; C, carried isolate.
*Allelic profiles for each gene are presented in the order, adhP, pheS. atr, ginA,
sdhA, g/cK, tkt.
128
9.4.iii Mobile genetic elements within the glcK gene.
PCR amplification of the internal fragment of the glcK gene in eight isolates of
ST-67 from the bovine collection produced a 3.0 kb band instead ofO.6 kb band
that was observed in the remaining isolates (Figure 9.1). This increase in band
size was found to be due to a mobile genetic element, which was inserted at the
identical point in the glcK gene in each of the eight bovine isolates. This mobile
genetic element (2314 bp) contained one open reading frame (568 amino acids),
and a BLAST search yielded an approximate 50% identity to group II intron
reverse transcriptase. For the purposes of the analysis using concatenated
sequences, the nucleotide sequence of the mobile element was deleted from the
text of nucleotide sequences leaving the intact glcK allele.
Figure 9.1: Agarose gel
(l%) demonstrating the
PCR product (glcK gene)
in two strains of GBS.
Size of DNA
markers
(Base -pairs)
The first lane is the DNA
size marker, the second
shows a band of
approximately 600 bp
(control) and the third lane
shows a band of
approximately 3000 bp
due to the presence of an
insertion sequence.
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2036
1636
]0]8
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insertion
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9.4.iv Relationship betweenbovine and human isolates.
The seven clonal complexes of human strains as previously shown (Chapter 6)
are evident in Figure 9.2. The current analysis uses the UPGMA clustering
algorithm of MEGA, based on the DNA sequence of the concatenated alleles
and shows that human ST-I complex, ST-19 complex, ST-6 complex and ST -10
complex cluster together and separately from ST-17 complex and ST-23
complex (Figure 9.2). The bovine isolates are clustered together (n=1 03, (93%».
Human ST -17 complex, previously identified as having increased virulence in
neonates!", now groups within the main bovine cluster. Placement of human
ST-4 complex as an "out group" 'Ofthe bovine cluster rather than with the other
human lineages is an apparent rearrangement compared with our previous
analysis reflecting the different method of analysis based on concatenated
sequences. A minority of bovine isolates (n=S, 7%) are found within the main
human STs, ST-23, ST-19, and ST-2.lsolates from dog and goat cluster with the
human STs. The elephant isolate and human ST-22 and ST-26 do not appear
closely related to any of the clusters. Bootstrap values have been calculated and
those greater than 70% are shown against the branches in Figure 9.2. Bootstrap
values are percentages of 500 computer-generated trees produced by randomly
sampling the sequences and are shown at the nodes. Underlined sequence types
indicate sequence types to be pruned for further analysis.
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Figure 9.2: UPGMA tree of
bovine and human GBS
collections. ST, host, and clonal
complex are indicated.
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The analyses thus far show that human ST-17 complex groups more closely with
the bovine STs than with other human STs, but strong support for this
conclusion is lacking, given the low bootstrap values at these branches. To
further assess reliable structure within the tree the data were examined using
split decomposition analysis, which allows for the fact that real evolutionary data
may not be best described by a branching tree format, given that recombinational
events may have occurred within the population.
The split graphs representation of the structure is shown in Figure 9.3 and
indicates that several STs are distantly related to most others (underlined in
Figure 9.2). As the algorithm gives undue prominence to these distant STs,
better discrimination between bovine and human STs was obtained on the
majority of the dataset by repeating the analysis after removal of2 distant human
STs (ST-22, ST-26) and the 4 STs from other species (dog (ST-SI, ST-S4), goat
(ST-S6), elephant (ST-S2).
Figure 9.4 shows that the bovine STs are in a separate split from the human STs.
This bovine split also contains the human ST-I7 complex (significantly
associated with invasive neonatal disease). Other branches in Figure 9.4 show
the same groupings of STs apparent in Figure 9.1. It can be seen that apparently
clear phylogenetic relationships in the UPGMA dendrogram in Figure 9.2 are
more complicated and are represented by a network, which has been discussed in
Chapter 7. However while the presence of parallel splits in Figure 9.4 shows
ambiguous phylogenetic relationships between clusters of mainly human STs,
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the finding that the human ST-17 complex groups within a branch of bovine
strains is a clear and robust result.
Figure 9.3: Tree drawn by split decomposition showing relationships between
bovine and human GBS collections.
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Figure 9.4. Tree drawn by split decomposition showing relationships between
bovine and human GBS collections after removal of long branches.
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9.5 DISCUSSION:
We have shown that populations ofGBS from bovines and humans are largely
discrete, which is consistent with previous workI55.156, but have clear areas of
overlap. The phylogenetic evidence suggests that human ST-17, the
hyperinvasive neonatal clone157, has arisen from a bovine lineage.
In order to achieve this analysis, large carefully assembled collections ofGBS
isolates have been studied. The bovine isolates were collected from UK cases of
bovine mastitis between 1950 to present day. The human isolates belong to a
well-characterized global collection, which has been described in detail in
Chapter 6.
Excluding the ST-23 complex, which is more distantly related, the remainder of
the human GBS STs fall into one large group of related clusters. There is marked
diversity in this group of clusters (Figure 9.4), demonstrated by the parallel
branches of the split graphs, which reveal that the phylogenetic relationships are
complicated and are indicative of recombination.
The most prevalent human STs, other than ST-17 are ST-1, ST-19 and ST-23.
These STs have diverse capsular serotypes, exhibit more complicated
phylogenetic relationships and include both carried and invasive isolates
suggestive of opportunistic pathogenicity. Occasional bovine isolates are found
within these STs.
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In contrast, the bovine mastitis collection of isolates are generally lacking in
diversity. Almost two-thirds of bovine strains (73 (65.8%» are ST-67. ST-67 can
be found within a cluster of strains, which includes the human ST -17 complex.
Previous molecular studies have suggested that isolates of bovine origin are of
high diversity99.158,which is inconsistent with the data presented here. This may
reflect different typing approaches used or perhaps geographical bias, as all
bovine isolates were from the UK. Furthermore, the bovine GBS isolates studied
were collected from the 1950s onwards when pasteurisation and improved
methods of hygiene in dairy farms were routine. For these reasons a more clonal
population structure for bovine GBS may be expected.
The greater genetic diversity of the human lineages indicates that this may
represent or be descended from a parent population ofGBS. The clonal
expansion evident for the bovine STs suggests more recent evolution from the
parent population. The finding of the human neonatal hyperinvasive ST -17
complex within this cluster is a significant finding and is consistent with the
concept that this lineage was acquired from the bovine subpopulation of GBS
relatively recently.
In conclusion, it has been shown from this study that populations of GBS from
bovines and humans are largely discrete, but have clear areas of overlap. The
phylogenetic evidence indicates that human ST-17, the hyperinvasive neonatal
clone, has arisen from a bovine lineage. The epidemiology of human neonatal
GBS infection is that of recent and sustained emergence since the 1970s for
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reasons that have never been fully elucidated. It is intriguing to postulate that the
increase in GBS infection in human neonates may be at least in part due to the
relatively recent introduction of the GBS genetic lineage corresponding to ST-17
complex into humans from cattle. The finding that ST-17 complex accounts for a
proportion of adult carried isolates (Table 9.1) suggests it is now autonomously
circulating within the human population. Further changes in animal husbandry
are therefore unlikely to alter disease prevalence in neonates. Nevertheless this
represents an example of a pathogen that has jumped the species barrier. Further
investigation of this model will require more extensive sampling of bovine and
human isolates and their characterisation by MLST and related techniques.
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Chapter 10: Conclusions.
The aims of this project were to develop a multilocus sequence typing system for
OBS. The system has been validated on a global collection of human OBS
isolates isolated from carriage and invasive disease. The population biology of
OBS was investigated on assembled collections ofOBS representing human
carriage and disease in neonatal and adult groups from a single geographical area
(Oxford, UK). Finally, the relationship between human and bovine OBS has
been explored.
The MLST system developed for OBS proved to be highly discriminatory when
compared with the current gold standard typing method for OBS, capsular
serotyping. A database of isolates and a website for OBS (www.sagalactiae.net)
has been established and is in the public domain.
OBS is the most common cause of neonatal infectious disease in Oxford, with
rates of infection of 0.94/1 000 live births, which approximate to the published
national statistics. OBS is a common pathogen in adults in Oxford, particularly
in pregnant women (18.0/100,000) and the over 60 years age group
(2.9/1 00,000). A large carriage study involving 748 pregnant women has been
undertaken and has shown that 21.3% of women in the Oxford area are
colonised vagi no-rectally by OBS at the time of delivery.
A collection of almost 300 OBS isolates from asymptomatic pregnant women
and neonatal invasive disease from a defined geographical area of the UK over a
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similar time period was assembled. Analysis of population structure has shown
that there are 6 major clusters ofGBS, all of which contain isolates from
carriage and neonatal invasive disease. The relationships between the major
complexes was best depicted as a network rather than branching lines and was
consistent with the presence of recombinational events occurring in the
population ofGBS that interfere with a tree like branching structure of the
population.
One clonal cluster, ST -17 complex, was significantly associated with neonatal
invasive disease (odds ratio 3.4, p-value 0.00003), particularly late onset
infections (odds ratio 6.0, p-value 0.000002). Furthermore the invasiveness of
this clonal complex appears to be independent of capsular type III. This raises
the possibility that a factor other than capsular type III may be responsible for
virulence of this clonal complex in neonates. The remaining GBS complexes
were successful well-adapted complexes, as indicated by their prevalence in the
population of both carriage and invasive isolates.
In contrast, hypervirulent clones were not identified in an investigation of GBS
isolates from adults with invasive disease in the age group> 60 years. Clonal
complexes that were prevalent in asymptomatic carriage were also successful as
pathogens in this setting.
When a collection of bovine derived GBS was investigated and compared with a
global collection of human isolates, the populations ofGBS from bovines and
humans were shown to be largely discrete but have clear areas of overlap. A
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particularly interesting finding was that human ST-17 complex, the
hyperinvasive neonatal clone, has arisen from a bovine lineage.
The epidemiology of human neonatal GBS infection is that of recent and
sustained emergence since the 1970s for reasons that have never been fully
elucidated. It is intriguing to postulate that the increase in GBS infection seen in
human neonates may be at least in part due to the relatively recent introduction
of the GBS genetic lineage corresponding to ST-17 complex into humans from
cattle.
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Appendix 2: Documentation for Ethical Committee.
1. Letter confirming ethical approval
2. Patient information sheet
3. Consent form
4. Letter for General Practitioners.
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Oxford Radcliffe Hospitals '~l:kj
NHS Trust
CENTRAL OXFORD RESEARCH
ETHICS COMMITTEE
Manor House
Headley Way, Headington
Oxford OX3 9DZ
Tel: 01865 222547
Fax: 01865 222699
dms/em/COO.035
20 April 2000
Dr Nicola Jones
Department of Microbiology
John Radcliffe Hospital
Oxford OX3 9DU
Dear Dr Jones
Re: COO.035 - Carriage of Group B streptococci in pregnant women in the
Oxford Radcliffe Trust
Thank you for your letter dated] o" April 2000, addressing the concerns raised
by the Committee at their meeting on 3rd March. In accordance with the
authority set out in the Terms of Reference, I am happy to confirm ethical
approval and wish you every success with the study.
Please note:
• Ethical approval is valid for three years from the date of this letter. Annual
updates of the progress of the research and a report of the outcome are
required. (A reminder letter will be sent when these reports are due).
• No significant changes to the research protocol should be made without
appropriate research ethics committee/chairman's approval. Any deviations
from or changes to the protocol which increase the risk to subjects, or affect
the conduct of the research, or are made to eliminate hazards to the research
subjects, should be made known to COREe.
• COREC should be made aware of any serious adverse events.
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• Whilst the study has received approval on ethical grounds, it is necessary for
you to obtain management approval from the relevant Clinical Directors and/or
Chief Executive of the Trusts (or Health Boards/DHAs) in which the work will
be done.
I should be very grateful if you could send me a copy of any publication which
may arise from this study.
Cont ...
NB: Any research which will be conducted on NHS patients or staff, and
which has been approved by a research ethics committee must carry the
appropriate indemnity. May I remind you that COREC final approval is
contingent on the appropriate indemnity being in place.
Yours sncerely,
Dr C J Chapman
Chairman
Central Oxford Research Ethics Committee
Central Oxford Research Ethics Committee {COREC)
--
COREC No: COO.035
Title of Project: Carriage of Group B streptococci in pregnant women in
the Oxford Radcliffe Trust
The following documents have been approved ~ COREC
Date/Version Approved
Patient Information Sheet and 2004.00 v
Consent Form 2004.00 v
GP Letter 2004.00 v
Terms of Reference, Standard Operating Procedures and a list of members of
the Ethics Committee are available from the Research & Development office
on request.
INDEMNITY
The purpose of an indemnity arrangement for a researcher is to provide legal protection in the
event of a researcher led unforeseen adverse circumstance. however minimal the risk. arising
during the course of a research project. The indemnity applies to the Senior Investigator in the
project and automatically covers any other generally more junior colleagues associated with
the project. There are various types of indemnity dependent on the circumstances of the
researcher and the nature of the research project. Staff employed in the NHS Trust Hospitals
should ensure that they are properly protected by the appropriate indemnity approved by the
Trust Chief Executive or Medical Director.
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Department of Microbiology
John Radcliffe Hospital
Oxford OX3 9DU
Tel 01865 220125
Fax 10865220890
Email: nicola.jones@ndcls.ox.ac.uk
zo" April 2000
Version 1
COREC: COO.035
PREVENTING INFECTIONS IN THE NEWBORN BABY
THE HORTON HOSPITAL GBS CARRIAGE STUDY
Information sheet for potential participants
You are being invited to take part in a research study. Before you decide, it is
important for you to understand why research is being done and what it will
involve. Please take time to read the following information carefully and discuss
it with friends, relatives and your GP, if you wish. Ask us if there is anything
that is not clear or if you would like more information. Take time to decide
whether or not you wish to take part.
Consumers for Ethics in Research (CERES) publish a leaflet entitled
"Medical Research and You". This leaflet gives more information about medical
research and looks at some questions you may want to ask. A copy may be
obtained from CERES, PO Box 1365, London N16 OBW.
Thank you for reading this.
What is the purpose of the study?
The Obstetric and Microbiology departments in the Oxford area are conducting a
study over a twelve month period which aims to see how frequent a particular
germ called GROUP B STREPTOCOCCUS is in pregnant women at the time of
delivery oftheir baby.
Group B streptococcus, or GBS, is a germ (bacterium) which lives harmlessly in
the vagina of healthy women. On rare occasions, GBS can spread to the newborn
baby and cause severe infection.
Currently we do not know how many women in the UK have GBS. We estimate
that it is roughly 15-20% of all women. It is currently not clear how doctors and
midwives should be treating pregnant women in whom GBS is detected.
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Why have I been chosen?
All women who are in the final few weeks of pregnancy will be asked to
participate. Over the course of the year it is hoped that 1000 women will take
part.
Do I have to take part?
It is up to you to decide whether or not to take part. If you decide to take part
you will be given this information sheet to keep and be asked to sign a consent
form. You are still free to withdraw at any time from the study without giving a
reason. This will not affect the standard of care you receive.
What will happen if I take part?
If you agree to take part in the study, a single swab will be taken from the rectal
and vaginal areas at the time of your first examination during your labour. This
takes less than one minute and does not require an internal examination. It is a
safe and easy procedure which would not harm you or your baby in any way.
You will also be asked to fill in a brief questionnaire.
Will my taking part in this study be kept confidential?
All information which is collected about you during the course of the research
will be kept strictly confidential. Any information about you which leaves the
hospital will have your name and address removed so that you can no longer be
identified.
Your own GP will be notified of your participation in the study.
What will happen to the results of the research study?
The results of the study will be published in a medical journal approximately 12
months after the finish of the study. A copy of the results will be available from
Dr Nicola Jones (address above). You will not be identified in any report or
publication.
Who is organising and funding the research?
The Medical Research Council and Action Research, which are charitable
organisations, are funding the research.
Who has reviewed the study?
The Central Oxford Research Ethics Committee has approved this study.
Contact for further Information
Further information can be given by Dr Nicola Jones and Dr Derrick Crook,
Department of Microbiology, John Radcliffe Hospital, tel 01865 220125 or
Mrs Yvonne Jones, Senior Midwife, Horton Hospital, tel 01295 229462.
Thank you for taking part in the study.
You will be given the information sheet and a copy of the consent form to keep.
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Department of Microbiology
John Radcliffe Hospital
Oxford OX3 9DU
Tel 01865 220125
Fax 10865220890
Coree Number: COO.035
zo" April 2000
CONSENT FORM
PREVENTING INFECTIONS IN THE NEWBORN BABY
THE HORTON HOSPITAL GBS CARRIAGE STUDY
Researcher: Dr Nicola Jones, Microbiology Please initial box
1. I confirm that I have read and understand the information sheet dated 20th D
April 2000 (version 1) for the above study and have had the opportunity to ask
questions.
2. I understand that my participation is voluntary and that I am free to withdraw D
at any time, without giving any reason, without my medical care or legal rights
being affected.
3. I understand that sections of any of my medical notes may be looked at by D
responsible individuals from the John Radcliffe Hospital where it is relevant to
my taking part in research. I give permission for these individuals to have
access to my records.
4. I agree to take part in the above study. D
Name of Patient SignatureDate
Name of Person taking consent
(if different from researcher)
Date Signature
Researcher Date Signature
Please complete all 3 consent forms enclosed» I copy for patient; I to be kept with hospital notes: I for
researcher (send to Dr N Jones. GBS Carriage study. level 7 Dept of Microbiology JR Hospital).
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Department of Microbiology
John Radcliffe Hospital
Oxford OX3 9DU
Tel 01865 220125
Fax 10865 220890
Version 1
COREC: COO.035
zo" April 2000
PREVENTING INFECTIONS IN THE NEWBORN BABY
THE HORTON HOSPITAL GBS CARRIAGE STUDY
Information sheet for General Practitioners and Health Visitors
Dear Colleague,
Your patient . Date of Birth ..
Address .
has kindly agreed to take part in our study.
Background to the study: Group B streptococcus is the most common infectious cause of
neonatal morbidity and mortality in the UK. Currently we do not know how common GBS
carriage is in pregnant women. It is hoped that the information gained from this study will
be used in the formation of guidelines for the prevention of GBS disease in neonates.
Aims: To determine the carriage rate of GBS in women attending the antenatal clinic at the
Horton Hospital, Banbury.
Research Protocol: Midwives are being asked to recruit women in the final trimester of
pregnancy. An information sheet is available for potential participants. The midwife will
explain the purpose of the study and ask the patient to complete a consent form and fill in a
brief questionnaire. At the first routine examination in labour, the midwife will take a
vagino-rectal swab and collect some patient details for a second questionnaire. The swab,
consent form and questionnaires are sent to the JR hospital for analysis by hospital transport
services.
The study has been approved by the Ethics Committee in Oxford (COREC
CO.035). Results will be made available at the end of the study. For any queries
please contact Dr N Jones or Dr D Crook, Department of Microbiology, John
Radcliffe Hospital, Oxford, tel 01865 220125 or Mrs Yvonne Jones, Senior
Midwife, Horton Hospital, Banbury, 01295 229462.
Yours faithfully,
Nicola Jones
Specialist Registrar Department of Microbiology
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